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Abstract
The 4th Conference of the American Society for Nanomedicine
is being held March 28–30, 2014 at the Universities at Shady
Grove, Rockville, Maryland. The meeting’s theme is on defin-
ing the role of nanomedicines for nervous system diagnostics
and disease but balanced by broad and timely topics for nano-
technology. Nanoneuromedicine, as defined by the develop-
ment of small drug formulations for the diagnosis and treatment
of degenerative, inflammatory, infectious, vascular, addictive,
behavioral and metabolic disorders of the nervous system, will
provide a focus for each of the scientific sessions. This research
is interdisciplinary and it’s in its infancy. The hurdles that
preclude translation from bench to bedside would include its
delivery across the blood brain barrier, limiting nervous system
toxicities, and improving drug targeting to diseased brain sub-
regions. These all pose challenges. Multidisciplinary works in
neuroscience (neurobiology, neurochemistry, neurophysiology,
and neuroinflammation), bioimaging, and polymer chemistry to
facilitate outcomes for formulation manufacture will be vigor-
ously discussed. How drugs reach sites of action need include
neural cell specific subcellular compartments. The ASNM
meeting will showcase nanoneuromedicine research from lead-
ing investigators of divergent scientific backgrounds who de-
fine this new field. It will also serve as an incubator for devel-
oping investigators and broad new field discoveries. Welcome
to the conference and enjoy!
Keywords: Nanomedicine, Blood Brain Barrier; Product
translation, Neuroimaging, Diagnostics, Neurotherapeutics,
Drug targeting, Nanotoxicity
The board of directors of the American Society for
Nanomedicine (ASNM) is pleased to welcome you to our
March 28–30, 2014 conference held at The Universities of
Shady Grove, Rockville, Maryland. The meeting will foster
the vision and goals of the society to promote basic, clinical
and population-based research in nanotechnology, engineer-
ing, biochemistry, molecular biology, and medicine. A rich
program is offered that will educate all our delegates including
physicians, scientists, engineers, molecular biologists, statisti-
cians, and many others interested in this emerging and exciting
field. Opportunities will abound during the next several days
for vigorous exchange through the meeting and in subsequent
publications offered through Nanomedicine: Nanotechnology,
Biology and Medicine and the Journal of Neuroimmune
Pharmacology. Our short and long-term goals are to encour-
age primary and secondary preventive measures using state of
the art nanomedicine technologies to reduce the incidences of
a broad range of diseases. We trust the meeting will serve to
speed research efforts aimed at a better quality and duration of
life through the types of drug discovery and improved diag-
nostics being discussed at the conference. A significant focus
of these efforts is aimed towards promoting and facilitating the
formal training of our physicians, scientists, engineers, molec-
ular biologists, statisticians and other members and allied
healthcare providers in the nanotechnology, nanobiology and
nanomedicine fields.
The 2014 theme of the conference - nanoneuroscience -
focuses on drug delivery to the nervous system for substance
abuse, degenerative medicine, mental health, infectious dis-
eases, and cancer. This two and one-half day meeting features
scientific sessions on CNS drug and formulation design,
targeted delivery and toxicology, diagnostics at the nanoneural
interface, neuronanotherapeutics, neuroregenerative medicine,
bench to bedside translations and applications for
nanomedicines, legal, developmental, scientific and regulatory
obstacles for product translation, and how nanomedicines can
be used and harnessed for HIVeradication. We anticipate that
each of these cross-disciplinary sessions can readily provide
significant opportunities for early career investigators to meet
and interact with scientific and clinical leaders in the field as
well as provide opportunities for future collaboration amongst
investigators. The interaction with funding agencies, pharma-
ceutical companies, and other industry leaders will also be
available through the conference.
Andre Nel, MbChB, PhD, will open the meeting with his
keynote address “Nanomedicine: The Key to an Engineered
Approach to Medicine and Biology.” Dr. Nel is Chief and
Founder of NanoMedicine in the Department of Medicine,
University of California, Los Angeles (UCLA) with broad
expertise in the research of novel nanotherapeutic platforms
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for strong clinical translation. This presentation will set the
stage for the meeting, in toto.
Gregory Lanza, MD, PhD, FACC, Washington Univer-
sity, St. Louis and Kuan Wang, PhD, Academia Sinica
will chair the session on “CNS drug and formulation
design, targeted delivery and toxicology.” Speakers in-
clude Alexander Kabanov, PhD, Dr SCI, University of
North Carolina; Esther Chang, PhD, Georgetown Univer-
sity Medical Center; Bruce Hinds, PhD, University of
Kentucky; Steven Rannard, PhD, University of Liver-
pool; Jinjun Shi, PhD, Harvard Medical School; and
Wei-Yi Ong, National University of Singapore. This ses-
sion will discuss brain tumor targeting, transdermal ad-
diction therapy, and development of novel sustained re-
lease nanotherapies that include siRNA and particle
biodistribution.
Raj Bawa, PhD, Rensselaer Polytechnic Institute and
Andrew Salperstein, PhD, GSK Pharmaceuticals will lead
the session on “Scientific, regulatory and developmental ob-
stacles for product translation.” Presenters will include Scott
Livingston, BA, Livingston Securities; Joseph A. Frank, MD,
MS, Clinical Center and National Institute of Biomedical
Imaging and Bioengineering, National Institutes of Health;
Susan Rosenbaum, JD, Lauren Sciences LLC; Shivani
Ghaisas, Medical College of Wisconsin; and Thomas Ernst,
PhD, University of Hawaii Medical Center. This session will
serve as a bridge between the legal and scientific aspects of
new technologies being developed in diagnostics and in using
nanotechnologies for tissue regeneration and disease amelio-
ration. The focus will be innovation and translation.
Steve Jacobson, PhD, National Institute of Neurological
Disease and Stroke (NINDS) and Wah Chiu, Baylor College
will chair and present in the session on “Diagnostics at the
nanoneural interface.” This session also includes Elad Alon,
PhD, University of California, Berkley; Dipanjan Pan, PhD,
University of Illinois at Urbana-Champaign; Yuri
Lyubchenko, PhD, DrSc, University of Nebraska Medical
Center (UNMC); Steve Jacobson, PhD, NINDS; Linda Chang,
MD of the University of HawaiiMedical Center; andWahCui,
PhD, Baylor College of Medicine. The focus will be on novel
technologies to improve diagnostics and disease monitoring
for a range of neurologic and degenerative disorders.
Marianna Foldvari, PhD, University of Waterloo and
Avindar Nath, MD, NINDS, will chair the “Nanotherapeutics”
session. Speakers include Omid Farokhzad, MD, Brigham and
Women’s Hospital; Gregory Lanza, MD Washington Univer-
sity School of Medicine; Jagat Kanwar, PhD, Deakin Univer-
sity; Christine Pham, MD, Washington University, St. Louis;
Vladimir Muzykantov MD, PhD, University of Pennsylvania;
and Xiaoyuan Chen, PhD, National Institute of Biomedical
Imaging and Bioengineering. This session will cover novel
nanotherapeutics from the laboratory bench to the patient bed-
side for a range of neurologic and peripheral disorders.
Lajos Balogh, PhD, Nanomedicine & Nanotechnology,
Boston, and Omid Farokhzad, MD, Brigham and Women’s
Hospital will chair the session on “Neuroregenerative Medi-
cine.” Presentations from; KiBum Lee, PhD, Rutgers Univer-
sity; Kam Leong, PhD, Duke University; Matthew Kelso,
PharmD, PhD, UNMC;Michal ToborekMD, PhD, University
of Miami; and Marianna Foldvari, PhD will cover the promise
and perils for neuroregenerative medicine.
Jonathan Pollock, PhD, National Institute on Drug Abuse
and Elena Batrakova, PhD, University of North Carolina
College of Pharmacy will lead the session on “Bench to
Bedside: Applications for Nanomedicines.” This session
brings together Elena Batrakova, PhD; George Perry, PhD,
University of Texas, San Antonio; Surya Mallapragada, PhD,
Iowa State University; Michelle Bradbury, MD, PhD, Memo-
rial Sloan-Kettering Cancer Center; Gabriel Lopez-Berestein,
MD, University of Texas MD Anderson Cancer Center; and
Ravi Bellamkonda PhD, Georgia Institute of Technology and
Emory University. This session will focus squarely on the
newest avenues for nanomedicine research in combating brain
disease. It will cover critical research aspects from the cells to
humans.
A special session is devoted to early career investigators.
Michelle Bradbury, MD, PhD, Memorial Sloan-Kettering
Cancer Center and Sulie Chang, PhD, Seton Hall University
will lead this session. Lajos Balogh, PhD, Editor-in-Chief,
Nanomedicine NBM, will provide an editor’s view of
nanomedicine. Through an NIH R13 conference grant, the
society was able to provide 12 travel awards (oral and poster).
Additional presentations from the next generation of leaders
on critical advances in the field include Eric C. Peterson, PhD,
University of Arkansas for Medical Sciences; David Leong,
National University of Singapore; Julijana Ivanisevic, PhD,
The Scripps Research Institute; Janet Hsu, BS, University of
Maryland; and Xi Zhu, BS, Harvard Medical School.
Jeymohan Joseph, PhD, NIMH and May Wong, PhD,
NINDS will lead the session on “Nanomedicine for HIV
eradication in the brain and other reservoirs.” Speakers include
Andrew Owen, PhD, University of Liverpool; Jerome Zack,
PhD, UCLA; Stanley Schwartz and Jessica Reynolds, State
University of NYat Buffalo; Howard E. Gendelman, MD, and
Serguei Vinogradov, PhD, DrSc, UNMC. This session will
discuss in some depth how the latest avenues of nanomedicine
research have and will strongly impact the field of HIV/AIDS
for treatment and eradication.
A vigorous poster session will engage most of the topic
sessions with a strong focus on early career professionals.
Posters will be shown throughout the conference and show-
cased Friday night, March 28th.
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The meeting will wrap up with a round table discussion
moderated by Esther Chang, PhD and Howard E. Gendelman,
MD. The session will give all participants an opportunity to
discuss the future direction, innovation, and needs in the field.
Once again welcome and enjoy. We hope you find the
platform and discussions of great interest and the collabora-
tions and discussions exciting.
The conference was supported by the National Institutes of
Health, National Institute of Neurological Disorders and
Stroke R13 Scientific Conference grant 1R13NS083315-01;
Seton Hall University; UNMC; Carol Swarts, MD, Emerging
Neuroscience Research Laboratory, UNMC; ViiV Healthcare
Company; Springer publisher, Journal of Neuroimmune
Pharmacology.
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Thursday, March 27, 2014
6:00 p.m. American Society for Nanomedicine Leadership Dinner (by invitation)
Friday, March 28, 2014
7:00 a.m. – 5 p.m. Registration Desk Open
8:00 a.m. Welcome Esther Chang, PhD
Introduction to Lecture Howard E. Gendelman, MD
8:15 a.m. Keynote Address: Andre Nel, MBChB, PhD, University of California, Los Angeles
“Nanomedicine: The Key to an Engineered Approach to Medicine and Biology”
9:00 a.m. Session 1: CNS drug and formulation design, targeted delivery and toxicology
Co-Chairs: Greg Lanza, MD, PhD, FACC, Washington University, St. Louis
Kuan Wang, PhD, Academia Sinica
9:05–9:25 a.m. Alexander Kabanov, PhD, Dr SCI, University of North Carolina
“AVery High Capacity Polymeric Micelle Drug Delivery System”
9:25–9:45 a.m. Esther Chang, PhD, Georgetown University Medical Center
“BrainTumor-TargetingNanomedicine SensitizesGlioblastoma toChemotherapy and Improves Survival”
9:45–10:05 a.m Bruce Hinds, PhD, University of Kentucky
“Gated Carbon Nanotube Membranes for Transdermal Addiction Therapy”
10:05–10:25 a.m. Steven Rannard, PhD, University of Liverpool
“Emerging Platform Technologies for Nanotherapies”
10:25–10:45 a.m. Jinjun Shi, PhD, Harvard Medical School
“Self-Assembled Lipid-Polymer Hybrid Nanoparticles for Sustained siRNA Delivery”
10:45–11:05 a.m. Wei-Yi Ong, PhD, BDS, National University of Singapore
“Effect of Inhalation Exposure on Biodistribution of Nanoparticles, Including the Brain”
11:05–11:20 a.m. Break
11:20 a.m. Session 2. Scientific, regulatory and developmental obstacles for product translations
Co-Chairs: Raj Bawa, PhD, Rensselaer Polytechnic Institute: Bawa Biotech LLC
Andrew Spaltenstein, PhD, GSK Pharmaceuticals
11:25–11:35 a.m. Scott Livingston, BA, Livingston Securities
“The JOBS Act, Crowdfunding, and the Return of the Small IPO: Changing the Way Innovation is
financed on Wall Street”
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11:35–11:55 a.m. Joseph A. Frank, MD, MS, Clinical Center and National Institute of Biomedical Imaging and
Bioengineering, National Institutes of Health
“Stem Cell Imaging Bench to Bedside”
11:55–12:15 p.m. Susan Rosenbaum, JD, Lauren Sciences LLC
“Product Development and Translations: From Cancer to HIV and NeuroAIDS”
12:15–12:35 p.m. Thomas Ernst, PhD, University of Hawaii Medical Center
“Innovation and Translation into the Marketplace”
12:35–12:50 p.m. Shivani Ghaisas,Medical College of Wisconsin (Early Career Investigator)
“Development of a Nanoparticle-Based Mitochondrial-Targeted Antioxidant Therapy Platform for
Treatment of Chronic Traumatic Encephalopathy”
12:50–1:45 p.m. Box Lunch (available to purchase) and Poster Viewing
1:45 p.m. Session 3: Diagnostics at the Nanoneural Interface
Co-Chairs: Steve Jacobson, PhD, National Institute of Neurological Disease and Stroke
Wah Chiu, PhD, Baylor College of Medicine
1:50–2:10 p.m. Elad Alon, PhD, University of California, Berkeley
“Neural Dust An Ultrasonic, Low-Power Solution for Brain-Machine Interfaces”
2:10–2:30 p.m. Dipanjan Pan, PhD, University of Illinois at Urbana-Champaign
“Quantitative Imaging of Coronary Ruptured Plaque with Energy-Resolved Spectral Computed
Tomography and K-edge Metal Nanocolloids without Calcium Interference”
2:30–2:50 p.m. Yuri Lyubchenko PhD, DrSc, University of Nebraska Medical Center
“Amyloid Hypothesis for AD Insight from Single Molecule Experiments and Computational Analyses”
2:50–3:10 p.m. Steve Jacobson, PhD, National Institute of Neurological Disorders and Stroke
“Nanomedicine in Demyelinating Disease: Application to Diagnosis and Therapy in
Neuroinflammatory Disorders”
3:10–3:30 p.m. Linda Chang, MD, University of Hawaii Medical Center
“MR Studies to Assess HIV-Associated Brain Injury Current and Future Perspectives”
3:30–3:50 p.m. Wah Chiu, PhD, Baylor College of Medicine
“Electron Cryo-tomography of Cells and Protein Aggregates”
3:50–4:05 p.m. Break
4:20 p.m. Session 4: Nanotherapeutics
Chairs:Marianna Foldvari, PhD, University of Waterloo
Avindra Nath, MD, National Institute of Neurological Disorders and Stroke
4:25–4:45 p.m. Omid Farokhzad, MD, Brigham and Women’s Hospital
“Targeted Polymeric Nanoparticles from Discovery to Clinical Trials”
4:45–5:05 p.m. Greg Lanza, MD, PhD, FACC, Washington University School of Medicine
“Scanning Probe Technologies for Carotid Microthombus Diagnoses Using Spectral CT”
5:05–5:25 p.m. Jagat R. Kanwar, PhD, Deakin University
“Nanoformulated Cell Penetrating Survivin Mutant and Lactoferrin Induced Differentiation and P-
Glycoprotein Mediated Anti-Epileptic Drug Resistance Reversal”
5:25–5:45 p.m. Christine T.N. Pham, MD, Washington University, St. Louis
“Characterization of Nanoparticle Complement Interaction”
5:45–6:05 p.m. Vladimir Muzykantov MD, PhD, University of Pennsylvania
“Endothelial Nanomedicine”
6:05–6:25 p.m. Xiaoyuan Chen, PhD, National Institute of Biomedical Imaging and Bioengineering
“64Cu-Doped Nanoparticles for In Vivo Tumor Imaging and Therapy”
6:30–7:30 p.m. Poster Session I and Social Hour
Saturday, March 29, 2014
7:30 a.m. – 6 p.m. Registration Desk Open
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8:00 a.m. Session 5: Neuroregenerative Medicine: Promise and Perils
Co-Chairs: Lajos Balogh, PhD, AA Nanomedicine & Nanotechnology
Omid Farokhzad, MD, Brigham and Women’s Hospital
8:05–8:25 a.m. KiBum Lee, PhD, Rutgers University
“Nanotechnology Approaches For Controlling Stem Cell Fate”
8:25–8:45 a.m. Kam Leong, PhD, Duke University
“Cell-Topography Interactions and Neuronal Differentiation”
8:45–9:05 a.m. Matthew Kelso, PharmD, PhD, University of Nebraska Medical Center
“Neuroprotective Regulatory T Cells as Vehicles for Nanoformulated Growth Factor Delivery
Following Traumatic Brain Injury”
9:05–9:25 a.m. Michal Toborek MD, PhD, University of Miami
“Perspective for Nanotoxicology”
9:25–9:45 a.m. Marianna Foldvari, PhD, University of Waterloo
“Gene Therapy Approaches to Regenerating the Optic Nerve”
9:45–10:00 a.m. Break
10:00 a.m. Session 6: Bench to Bedside: Applications for nanomedicines
Co-Chairs: Jonathan Pollock, PhD, National Institute on Drug Abuse
Elena Batrakova, PhD, University of North Carolina, College of Pharmacy
10:05–10:25 a.m. Elena Batrakova, PhD, University of North Carolina, College of Pharmacy
“Carriers that Break Barriers”
10:25–10:45 a.m. George Perry, PhD, University of Texas, San Antonio
“Mitochondria at the Origin of Oxidative Stress”
10:45–11:05 a.m. Surya Mallapragada, PhD, Iowa State University,
“Nanomedicines for Neuroprotection and Neuroregeneration”
11:05–11:25 a.m. Michelle Bradbury, MD, PhD, Memorial Sloan-Kettering Cancer Center
“Ultrasmall Hybrid Inorganic Nanoparticle Probes for Brain Tumor Imaging”
11:25–11:45 a.m. Gabriel Lopez-Berestein, MD, University of Texas MD Anderson Cancer Center
“Targeting Neurons with Chitoisan Nanoparticles”
11:45–12:05 p.m. Ravi Bellamkonda PhD, Georgia Institute of Technology and Emory University
“Nanofiber and Nanocarrier Mediated Modulation of Cell Migration for Nerve Repair and Brain
Tumor Therapy”
12:05–1:15 p.m. Box Lunch (available to purchase) and Poster Viewing
1:15 p.m. Session 7: Early Career Investigators
Co-Chairs:Michelle Bradbury, MD, PhD, Memorial Sloan-Kettering Cancer Center
Sulie Chang, PhD, Seton Hall University
1:20–1:40 p.m. Lajos Balogh, PhD, Editor-in-Chief, Nanomedicine NBM (Elsevier)
“Nanomedicine: An Editor’s View”
1:40–2:00 p.m. Eric C. Peterson, PhD, University of Arkansas for Medical Sciences (Early Career Investigator)
“Nanomedicine and Toxicology”
2:00–2:20 p.m. David Leong, PhD, National University of Singapore (Early Career Investigator)
“Nanoparticle Induced Endothelial Leakiness Mechanism and Implications to Nanomedicine”
2:20–2:40 p.m. Julijana Ivanisevic, PhD, The Scripps Research Institute (Early Career Investigator)
“Metabolic Phenotyping to Functionally Characterize Brain Regions”
3:00–3:15 p.m. Janet Hsu, BS, University of Maryland (Early Career Investigator)
“Transport of ICAM-1-Targeted Nanoparticles Across Endothelial-Subendothelial Layers and Up-
take by Neurons”
3:15–3:30 p.m. Xi Zhu, BS, Harvard Medical School (Early Career Investigator)
“Self-Assembled Lipid-Polymer Hybrid Nanoparticles for the Sustained Delivery of Small Interfering
RNA”
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3:45–4:00 p.m. Group Photo
4:00–4:15 p.m. Break
4:15–4:45 p.m. ASNM Business Meeting (members and non members welcome)
4:45–6:15 p.m. Special Session: Poster Viewing (Early Career Investigator) and Early Career Investigator
Education Session
Chairs: Michelle Bradbury and Howard E. Gendelman
7–9:30 p.m. Meet the Professor/Young Investigator Dinner (by invitation)
Location: TBA
Sunday, March 30, 2014
8:30 a.m. – 11 a.m. Registration Desk Open
9:00 a.m. Session 8: Nanomedicine for HIV Eradication in Brain and Other Reservoirs
Co-Chairs: Jeymohan Joseph, PhD, National Institute of Mental Health
May Wong, PhD, National Institute of Neurological Disease and Stroke
9:05–9:25 a.m. Andrew Owen, PhD, University of Liverpool
“Sustained Release Formulations for HIV Therapy”
9:25–9:45 a.m. Jerome Zack, PhD, University of California, Los Angeles
“A Nanoparticle Approach to Targeting Latent HIV Reservoir”
9:45–10:05 a.m. Stanley Schwartz, MD, PhD, State University of New York at Buffalo
“Nanotherapies: Current and Future Challenges”
10:05–10:25 a.m. Howard E. Gendelman, MD, University of Nebraska Medical Center
“Nanoformulated Antiretroviral Therapy and the CNS”
10:25–10:45 a.m. Serguei Vinogradov, PhD, DrSc, University of Nebraska Medical Center
“Application of Targeted Nano-NRTI Cocktails against HIV Infection in the Brain”
10:45–11:05 a.m. Jessica Reynolds, PhD, State University of NY at Buffalo (Early Career Investigator)
“Pharmacokinetic and Immune-Dynamics of Multimodular particles for HIVand/or TB”
11:10 –11:30 a.m. Questions and Closing Remarks
Co-Chairs: Howard E. Gendelman and Esther Chang
11:30 a.m. Meeting Adjourned
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Keynote Address
0 01 . NANOMEDICINE: THE KEY TO AN
ENGINEERED APPROACH TO MEDICINE AND
BIOLOGY
Nel A. David Geffen School of Medicine, University of
California, Los Angeles 90095.
Since much of structure and function of biology is executed at
nanoscale level, this provides us with an exciting new oppor-
tunity to use the unique properties of engineered nanomaterials
for interrogation of disease, diagnosis, treatment, and imaging
at levels of sophistication not previously accomplished.
Nanomedicine can be defined as the design and synthesis of
biologically interactive nanoscale systems that enable the bio-
medical community to make advances in the prevention, diag-
nosis, and treatment of disease, maintenance and improvement
of human health, and providing chronic and acute pain relief
by leveraging significant advantages nanosystems hold over
traditional methods for sensing, imaging, reconstruction, de-
livery and interaction with biological systems. This vision is
being implemented by our UCLANanomedicine Division and
a multidisciplinary working group that performs basic, trans-
lational and clinical-based research using the unique properties
of a range of engineered nanomaterials to understand the
nano/bio interface as a launching pad for developing new
diagnostic and therapeutic modalities. Fabrication of a host of
nanostructures in a collaborative setting in the California
NanoSystems Institute (CNSI) is being coupled with advanced
chemical manipulation to develop diagnostics and therapeutics
for infectious disease, cancer, immunological disease. This
includes a multifunctional mesoporous nanoparticle imaging
and delivery system for therapeutics that are based on the
pathophysiology of disease and clinical-defined problems.
We also use high throughput screening and modeling ap-
proaches to assist nanomaterial design and safety assessment.
We envisage the use of nanotechnology and materials science
to develop a series of engineered approaches by physician/
scientists teams that tackle clinical defined disease problems.
SESSION 1: CNS DRUG AND FORMULATION
DESIGN, TARGETEDDELIVERYANDTOXICOLOGY
002. A VERY HIGH CAPACITY POLYMERIC
MICELLE DRUG DELIVERY SYSTEM
Kabanov A1, Jordan R2, Luxenhofer R3. 1University of North
Carolina at Chapel Hill, Chapel Hill, NC 27599-7362;
2Technische Universität Dresden, 3University Würzburg.
Polymeric micelles proposed as carriers for drug delivery in
the end of 80-ies by Kabanov’s and Kataoka’s groups have
now reached a clinical stage with one polymer micelle product
approved and number of others undergoing clinical trials. One
“value proposition” of polymeric micelles is their ability to
incorporate water-insoluble drugs. However, only few drugs
and polymeric micelle systems displayed loading capacities of
even 10–20 % (wt. drug/wt. drug and polymer) with most
others having lower capacities. We discovered that polymeric
micelles of poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-
butyl-2-oxazoline) (PBuOx) triblock copolymer PMeOx-
PBuOx-PMeOx have an unprecedented high loading capacity
of nearly 50 % for paclitaxel (PTX), docetaxel (DTX) as well
as other drugs and multi-drug combinations. Such loading
capacity is due to a unique multi-domain structure of the
PBuOx hydrophobic core, which can accommodate both hy-
drophobic and polar groups of many drug molecules. As a
result the amount of the polymer used is greatly decreased
(e.g. nearly 50 times compared to Chremophor EL in Taxol)
and the maximal tolerated dose (MTD) increased (e.g. in a
mouse 7 times vs. Taxol). Due to greater exposure at the
increased and safe dose the drug more efficiently kills the
tumor cells resulting in more efficient therapy. Multiple drugs
and drug combinations can be solubilized providing for a
versatile drug delivery platform for 1) rescuing “undruggable”
molecules; 2) reformulating existing drugs; and 3) creating
multi-drug combinations that affect synergistic pathways and
more efficiently cure the disease.
Supported by: Cancer Nanotechnology Platform Partnership
grant (U01 CA116591).
003. BRAIN TUMOR-TARGETING NANOMEDICINE
SENSITIZESGLIOBLASTOMATOCHEMOTHERAPY
AND IMPROVES SURVIVAL
Chang EH1,2, Kim SS1, Rait A1, Kim E2, Pirollo KF1.
1Department of Oncology, Lombardi Comprehensive Cancer
Center, Georgetown University, Washington, DC 20057;
2SynerGene Therapeutics, Inc., Potomac, MD 20854.
Temozolomide (TMZ)-resistance in glioblastoma multiforme
(GBM) has been linked to upregulation of O6-methylguanine-
DNA methyltransferase (MGMT). However, therapy for
GBM is often limited by lack of efficient delivery across the
blood brain barrier (BBB). We have developed a systemically
administered, tumor-targeting nanodelivery system compris-
ing a liposome directed to the tumor by a single-chain anti-
body fragment targeted to the transferrin receptor. This self-
assembled nanocomplex (scL), shown to encapsulate various
payloads including nucleic acid-based therapeutics, diagnostic
imaging probes, small molecules, and chemotherapeutic
agents, exhibits exquisite tumor specificity in numerous pre-
clinical studies. The nanocomplex carrying the wtp53 gene
(SGT-53) is currently being evaluated in a number of clinical
trials where it has been shown to be well tolerated and has
demonstrated anti-cancer activity. Here, we show that
SGT-53 crosses the BBB and efficiently targets GBM, as
well as cancer stem cells (CSCs). Wtp53 was previously
S8 J Neuroimmune Pharmacol (2014) 9 (Suppl 1):S1–S38
shown to downmodulate MGMT. Thus, we also evaluated
the effect of scL-p53 on MGMT expression in a mouse
model of GBM. Systemic delivery of SGT-53 down-
modulated MGMT and induced apoptosis in intracranial
GBM xenografts. The combination of SGT-53 and TMZ
increased the anti-tumor efficacy of TMZ with enhanced
survival benefit in a mouse model of highly TMZ-resistant
GBM. SGT-53 sensitized both CSCs and bulk tumor cells
to TMZ, increasing apoptosis. These results suggest that
combining SGT-53 with standard TMZ treatment could be
a more effective therapy for GBM.
004. GATED CARBON NANOTUBE MEMBRANES
FORTRANSDERMAL ADDICTION THERAPY
Hinds B. Chemical and Materials Engineering, University of
KY, Lexington, KY 40506.
Addiction treatment is one of the most difficult health care
challenges due to the mixture of complex changing neuro-
chemical pathways and psychological behavior. Generally the
most effective treatments require psychological monitoring/
counseling and adaption of therapeutic techniques. For large
population addiction, such as nicotine, it is cost and time
prohibitive to have face to face meetings. A promising system
is where a dosing regiment (within a doctors’ prescription
limit) can be remotely programmed to account for daily envi-
ronmental factors, patient input, and counselor feedback from
phone interviews or internet-based surveys. Needed for this
system is an ultra-low power, compact, and programmable
delivery device not currently available with electroporation or
mechanical pumps.
Carbon nanotubes (CNTs) are electrically conductive and
support dramatic internal flow rates [Nature 2005]. These
properties are nearly ideal for introducing efficient electro-
phoretic and electro-osmotic flow [Nat. Nanotech 2011] to be
used as the basis of a programmed transdermal delivery de-
vice. These CNT membranes are 100 fold more energy effi-
cient than conventional nanoporous materials allowing watch
battery operation for 1 week. An in-vitro cell, composed of a
reference electrode, reservoir solution, CNT membrane elec-
trode, gel contact and human skin sample were assembled in a
Franz cell. Therapeutically useful fluxes for Nicotine treat-
ment were controllably switched between, with 0.56 and 2.0
micromole/cm2-hr at 0 mVand -600 mV respectively [PNAS
2010]. Prototype device studies on hairless guinea pigs
showed active switching [J. Pharm. Sci. 2012] with
further refinement of time dependent dosing using mi-
crodialysis membrane assays in vitro. Wireless
Bluetooth programmed control with basic survey input
was also demonstrated allowing for the combination of
psychological and physiological approaches in addiction
treatments.
Supported by: NIH NIDA R01DA018822
005. EMERGING PLATFORM TECHNOLOGIES FOR
NANOTHERAPIES
Rannard S and Owen A. Department of Chemistry, University
of Liverpool, Liverpool, UK L69 7ZD.
Nanomedicines have been very successful in the devel-
opment of new therapies from existing active pharma-
ceutical ingredients (APIs) and have heavily targeted
direct intravenous delivery or oral administration.
Diseases/conditions ranging from cancer to organ rejec-
tion are treated daily by nanoparticle technologies. The
most successful platform to date is the nanomilling of
poorly soluble APIs to form solid drug nanoparticles,
which are orally dosed although extended research
programmes and clinical studies are investigating the
benefits of milled SDNs for sustained delivery from
depot injections. Material chemistry has a strong role
to play in the provision of options for platform ap-
proaches to nanotherapy development. Nanomilling is
not applicable to all APIs and the rapid production of
libraries of nanomilled SDNs is time consuming. A
recent platform has been developed that utilizes novel
freeze-drying approaches and as little as 1 mg of API
per library member. Diversity of SDN chemistry, size
and surface charge may be readily studied across 100 s
of candidates. New polymeric nanocarriers are also be-
ing developed that have the benefits of ideal dendrimers
but the flexibility and scalability of conventional poly-
meric materials. This overview will examine the ad-
vances in freeze drying technologies and new polymeric
nanocarrier systems and relate their value to the treat-
ment of HIV.
006. SELF-ASSEMBLED LIPID-POLYMER HYBRID
NANOPARTICLES FOR SUSTAINED SIRNA
DELIVERY
Shi, J. Brigham and Women’s Hospital, Harvard Medical
Center, Boston, MA 02115.
RNA interference (RNAi), which can selectively knock-
down target genes, has shown great potential in the
treatment of various diseases including cancer. Thus
far, numerous nanoparticle (NP) platforms, such as
lipoplexes and polyplexes, have been developed to fa-
cilitate the safe and effective delivery of small interfer-
ing RNA (siRNA), which represents a major hurdle for
the clinical applications of RNAi. Nevertheless, these
NP systems lack the sustained siRNA release property,
and thus can only induce transient gene silencing due to
the short lifetime of siRNA. Therefore, it is expected
that the development of controlled-release siRNA NPs
will lead to sustained gene silencing and more effective
cancer treatment.
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Herein, we present a robust NP platform for safe and
effective siRNA delivery in a sustained manner, which
can be developed through the self-assembly of biode-
gradable and biocompatible polymers and lipids. The
lipid-polymer hybrid NPs show excellent knockdown
efficacy at low doses of siRNA. More importantly, these
NPs can control the temporal release of siRNA, with
the half-release time of~9 days, for sustained silencing
of target gene expression. For example, results demon-
strate that the expression of PHB1 can be effectively
inhibited for over 2 weeks after short-term transfection
with the NPs. The NP-mediated sustained silencing of
PHB1 in turn generates more effective tumor cell
growth inhibition in vitro and in vivo than the
lipofectamine-siRNA complexes. Furthermore, this NP
platform has been applied to deliver siRNAs against
drug resistance and chemotherapeutic drugs for syner-
gistic cancer treatment. We expect that the lipid-polymer
hybrid NP platform with the property of sustained
siRNA release could be of interest in both fundamental
biological studies and clinical applications.
007. EFFECT OF INHALATION EXPOSURE ON
BIODISTRIBUTIONOFNANOPARTICLES, INCLUDING
THE BRAIN
Ong WY. Department of Anatomy, Yong Loo Lin School of
Medicine, National University of Singapore 119597.
Background: Gold nanoparticles (AuNPs) are finding in-
creased use in therapeutics and imaging. This study was
carried out to determine the biodistribution and gene effects
of AuNPs after inhalation exposure. Methods Male Wistar
rats were exposed for 15-days to airborne agglomerates of
AuNPs of similar size distribution and number concentra-
tion (1×10(6) particles/cm(3)), but two different primary
diameters of 7 nm or 20 nm, and whole body
biodistribution of Au determined by ICP-MS. Possible gene
expression changes were also determined in the ling, kidney
and hippocampus by microarrays. Results: After inhalation
exposure, the highest mass concentration of agglomerates
containing 7-nm AuNPs were deposited in the lungs,
followed by brain regions including the olfactory bulb,
hippocampus, striatum, frontal cortex, entorhinal cortex,
septum, cerebellum; aorta, esophagus, and kidney. Eight
organs/tissues especially the brain retained greater mass
concentration of Au after inhalation exposure to agglomer-
ates of 7-nm than 20-nm AuNPs. Macrophage mediated
escalation followed by fecal excretion is the major pathway
of clearing inhaled AuNPs in the lungs. Microarray analy-
ses of the lung showed mostly downregulated genes related
to muscle and secretion. The hippocampus showed mostly
downregulated genes, related to the cytoskeleton and neurite
outgrowth. In comparison, after intravenous injection, Au
was rapidly and consistently accumulated in liver (49.4+/-
50.4-72.2+/-40.5 ng/g) and spleen (8.4+/-5.0-9.5+/-6.4 ng/g).
Conclusion: The above results demonstrate differential
biodistribution of AuNPs in the body after inhalation exposure
or intravenous injection, and gene expression changes in target
organs.
SESSION 2. SCIENTIFIC, REGULATORY AND
DEVELOPMENTAL OBSTACLES FOR PRODUCT
TRANSLATIONS
008. THE JOBS ACT, CROWDFUNDING, AND THE
RETURN OF THE SMALL IPO: CHANGING THE
WAY INNOVATION IS FINANCED ONWALL STREET
Livingston S. Livingston Securities, New York, NY 10022.
The biotech revolution was built by 2 million share IPOs at $8
The internet was built by 3 million share IPOs at $12.
Emerging technology companies in the late 80s and 90s had
access to IPOs to help them raise capital to scale up their
breakthrough technologies. In addition, having a public com-
pany and a ticker symbol offered many other advantages to
help companies grow.
A number of companies succeeded wildly, many companies
failed, and many other companies were acquired and merged
into bigger companies. Along the way the biotech industry
created millions of jobs, offered new treatments for diseases,
and created over a trillion dollars of wealth.
After the dot com bust a number of rules were put into
place that changed this environment. While many of the
changes were needed, unforeseen impacts also arose and
the small IPO effectively disappeared in the US.
The breakthrough technologies of the 21st century (nanotech-
nology, personalized medicine, regenerative medicine, etc)
have had to grow up in a much different environment than
the biotechs of the early 90s. Many companies have
complained that a lack of access to scale up capital has been
their main challenge.
In April of 2012 the Congress passed and President Obama
signed the JOBS Act into law. One result of the JOBS Act has
been a significant increase in the IPO markets, and in partic-
ular the smaller IPO, which has had a major impact on
financing disruptive nano-bio companies.
Livingston Securities participated in 31 equity capital
markets transactions (IPOs and secondaries) in 2013,
vs 25 in 2012 and 5 in 2011. We have been very active
in helping emerging nano-bio companies raise capital in
the public and private markets over the last few years,
and are well versed and positioned to help companies
understand how these changes can impact their capital
raising efforts, as well as to help institutional and indi-
vidual investors make smart investment decisions in the
new post-JOBS Act environment.
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009. STEM CELL IMAGING BENCH TO BEDSIDE
Frank JA. Clinical Center and National Institute of Biomedi-
cal Imaging and Bioengineering, Bethesda, MD 20892.
Over the past decade there has been increasing interest in the
potential use cellular therapies to treat diseases. Labeling
transplanted cells to be identified on MRI offers the ability
to track the migration of transplants cells into tissues, as part of
treatment strategy is information that is potentially unavailable
by other methods. Various techniques have been developed to
label cells with MRI contrast agents. Both experimental and
clinically used paramagnetic (gadolinium, manganese) and
superparamagnetic iron oxide (SPION) nanoparticles have
been used to label stem cells, progenitor cells, immune cells
and cancer cell lines for cellular MRI studies. Although there
are a variety of agents that have been used to tag cells for
in vivo imaging studies, this presentation will focus on the use
ofMRI contrast agents to track cells. I will also discuss the use
of ferumoxytol, a recently approved ultrasmall SPION for iron
deficiency anemia that can be used to magnetically label cells
ex vivo for cellular MRI. In order to label cell In particular I
will address specific questions including: 1) is there a need to
track cells by MRI; 2) what agents can be used to label cells
with the goal to translate from the bench to bedside; 3) how
long can labeled cells be tracked by MRI and what is needed
to noninvasively determine cell function, survival or differen-
tiation; 4) what happens to the label in tissues; and 5) Will
magnetic cell labeling be used in the clinical by 2020? Part of
the presentation will discuss the challenges in taking magnetic
cell labeling with SPION to the clinic trials, the possible
preclinical data for regulatory approval, along with the poten-
tial of where magnetic labeling of cell tagging may be useful
in cell therapy.
010. PRODUCT DEVELOPMENT AND TRAN
SLATIONS: FROMCANCERTOHIVANDNEUROAIDS
Rosenbaum S. Lauren Sciences LLC, New York, NY 10128
The process of commercializing an invention, taking a dis-
covery and making it into a medicine, getting it from the
Ph.D.s and giving it to the patients, is referred to as going
from “bench to bedside”. But, what exactly does this mean?
And, what does it entail?
Product development, or translations from research into de-
velopment to clinic, will be explored by way of example. The
case study will be of Lauren Sciences LLC, a start up biotech
with a breakthrough technology in nanomedicine, and a cur-
rent focus on neurodegenerative diseases. Lauren Sciences
has a patent estate of 10 patent families, and 15 papers pub-
lished in peer-reviewed scientific journals.
Lauren Sciences is developing transformative V-SmartTM
therapeutics based on its groundbreaking innovation – the V-
SmartTM targeted drug delivery system. V-SmartTM is a
novel nanovesicle platform technology invented at Ben
Gurion University. V-SmartTM nanovesicles can cross the
BBB, target inside the brain, selectively release at target sites
and be administered systemically.
Lauren Sciences pipeline includes transformative V-SmartTM
therapeutics for: Parkinson’s, AIDS, Alzheimer’s, ALS, Brain
Cancer and LSDs. Lauren Sciences recently demonstrated
successful delivery, by i.v. administration, of: (1) GDNF-
loaded V-SmartTM nanovesicles targeted to dopaminergic
neurons in the brain for the treatment of Parkinson’s (support-
ed by The Michael J. Fox Foundation), and (2) Tenofovir-
loaded V-SmartTM nanovesicles to the brain for the treatment
of neuro-HIV (supported by The Campbell Foundation).
The challenges of product translations, whether scientific,
regulatory or developmental, require an integrated ap-
proach and a strategic plan. All applications of a product,
whether for cancer or AIDS, will satisfy unmet medical
needs. It takes people and project synergies to make it
happen. The new model used by Lauren Sciences cuts to
the chase.
011. INNOVATION AND TRANSLATION INTO THE
MARKETPLACE
Ernst T. Department of Medicine, University of Hawaii,
Honolulu, HI 96813.
The ultimate goal of biomedical research, including
nanomedicine, is to improve human health. This requires that
basic research findings and innovations are eventually trans-
lated into the commercial realm. The two major pathways
towards commercialization of intellectual property (IP) are 1)
creation of a startup company, and 2) licensing of the IP to an
existing business. The choice between these two paths is
partially driven by the potential market size of the final prod-
uct, with option 1 (startups) being more favorable for larger
markets (typically $1 billion or greater). Compared to licens-
ing, creation of a startup company to commercialize IP has
several potential advantages, due to a tight focus of the new
company on turning the IP into a marketable product. Diffi-
culties and disadvantages associated with commercialization
via a startup company include 1) potentially high risk of failure
due to the narrow focus, typically on a single product, 2) the
need to raise capital funds, 3) potentially long time frame
for entry into the market (years), and 4) the inventors may
lose control over research and product development.
However, the laser-like focus of typical startup companies
also maximizes chances for success in commercializing
the IP. Also, since startup companies take on early risk,
successful commercialization can result in large gains to
the inventors and the Universities where the research was
conducted. Ultimately, inventors may draw a substantial
reward from seeing their invention being turned into a
real-life product that will benefit patients.
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012. DEVELOPMENT OFA NANOPARTICLE-BASED
MITOCHONDRIAL-TARGETED ANTIOXIDANT
THERAPY PLATFORM FOR TREATMENT OF
CHRONIC TRAUMATIC ENCEPHALOPATHY
Ghaisas S1, Brenza T2, Zenitsky G1, Vela-Ramirez J2,
Anantharam V1, Joseph J3, Kalyanaraman B3, Kanthasamy
A1, Mallapragada S2, Narasimhan B2 and Kanthasamy AG1.
1Departments of Biomedical Sciences, and 2Chemical and
Biological Engineering, Iowa State University, Ames, IA
50011; 3Department of Biophysics, Medical College of
Wisconsin, Milwaukee, WI 53226.
Effective neuroprotective strategies to treat chronic traumatic
encephalopathy (CTE) induced neurodegenerative diseases,
such as Parkinson’s (PD) and Alzheimer’s, are urgently needed.
Recently, we showed that mitochondria-targeted antioxidants
can be effective against dopaminergic neuronal degeneration in
cell culture and animal models of PD. The goal of this study is
to evaluate the efficacy of a novel mitochondrial-targeted anti-
oxidant nanoformulation, MitoApocynin Encapsulated Nano-
particles (MEN), in cell culture and animal models of CTE.
After first encapsulating mitoapocynin with poly (sebacic acid)
into MEN, we then determined that 30-100 μg of MEN was
optimal for in vitro studies as this dose range did not cause any
significant toxicity over a 24 h period in neuronal cultures.
Additionally, 30 μg of 1 % MEN protected against glutamate-
induced excitotoxicity in primary cortical neurons based on
Sytox andMTTassays. To develop a robust in vitro CTEmodel
for testingMEN’s efficacy, we used the Cell Injury Controller II
system to deliver strain-induced trauma to in vitro cell cultures
and brain slices. Stretch injury using primary cortical neurons
consistently showed elevated caspase-3 enzymatic activity vs
sham-blast, indicating the model’s viability for determining
apoptotic cell death after blast induced stretch injury. In devel-
oping animal studies of CTE, we examined behavioral and
neurochemical changes in a mouse blast injury model.
C57BL/6 blackmice exposed to a single-blast or repeated blasts
of 20 psi showedmild behavioral and neurochemical deficits on
day one post-blast but recovered by day seven post-blast. We
also measured neuroinflammatory markers including TNFα,
IL-1β, IL-6, iNOS and MMP9 mRNA. Current studies are
investigating MEN in brain slice and mouse models of CTE.
Together, these findings indicate that nanoparticle-encapsulated
mitochondria-targeted antioxidants may represent a novel
nanomedicine-based treatment strategy for CTE.
SESSION 3: DIAGNOSTICS AT THE NANONEURAL
INTERFACE
013. NEURAL DUSTAN ULTRASONIC, LOW-POWER
SOLUTION FOR BRAIN-MACHINE INTERFACES
Alon E, Seo DJ, Carmena J, Rabaey J, Maharbiz M. University
of California, Berkeley, Berkeley, CA 94720.
A major hurdle in brain-machine interfaces (BMI) is the lack
of an implantable neural interface system that remains viable
for a lifetime. I will discuss Neural Dust, a concept developed
with DJ Seo, Michel Maharbiz, Jose Carmena, and Jan
Rabaey (http://arxiv.org/abs/1307.2196), which explores the
fundamental system design trade-offs and ultimate size, pow-
er, and bandwidth scaling limits of neural recording systems
built from low-power silicon (CMOS) circuitry coupled with
ultrasonic power delivery and backscatter communication. In
particular, we propose an ultra-miniature as well as extremely
compliant system that enables massive scaling in the number
of neural recordings from the brain while providing a path
towards truly chronic BMI. These goals are achieved via two
fundamental technology innovations: 1) large numbers of 10 –
100 micron scale, free-floating, independent sensor nodes, or
neural dust, that detect and report local extracellular electro-
physiological data, and 2) a sub-cranial interrogator that es-
tablishes power and communication links with the neural dust.
014. QUANTITATIVE IMAGING OF CORONARY
RUPTURED PLAQUE WITH ENERGY-RESOLVED
SPECTRAL COMPUTED TOMOGRAPHY AND K-
EDGE METAL NANOCOLLOIDS WITHOUT
CALCIUM INTERFERENCE
Schirra CO1,2, Senpan A1, Roessl E2,Thran A2, Scott MJ1,
Gaffney PJ1, Wickline SA1, Proksa R2, Lanza GM1, Pan D2,3.
1Philips Research, 22335 Hamburg, Germany; 2CTRAIN,
Division of Cardiology, Washington University School of
Medicine, St. Louis, MO 63110; 3Department of Bioengineer-
ing, University of Illinois at Urbana-Champaign, Beckman
Institute, Carle Foundation Hospital, Urbana, IL 61820.
Emerging development of SPECTRAL CT and the opportu-
nity for k-edge-based molecular imaging capability is expect-
ed to eliminate coronary calcium interference and offer rup-
tured coronary plaque detection. Spectral CT generates im-
ages based on unique spectral footprints of specific metals
based on K-edge differences in the X-ray energy band, which
will also permit detection and quantification of ruptured
plaque with fibrin-specific K-edge contrast agents. The goal
of these experiments was to introduce new class of molecular
imaging agents, based on bismuth (Bi) and ytterbium (Yb), to
detect microthombus in ruptured atherosclerotic plaque in
combination with an advanced statistical image reconstruction
method for improved signal-to-noise ratio (SNR). We hypoth-
esized that rapid Spectral CT imaging in combination with
targeted contrast agents that carry K-edge material will pro-
vide a revolutionary improvement in the recognition, quanti-
fication, and stratification of coronary plaque instability and
guide medical decisions for early percutaneous intervention
versus aggressive medical therapy. Metal nanobeacons
(MNB) were designed and synthesized by concentrating a
high payload of metals within a vascularly constrained
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(~200 nm) particle. MNBs targeted to fibrin acellular in vitro
phantoms and human carotid specimens ex vivo revealed high
contrast signal and intravascular constraint. Noninvasive
in vivo detection of thrombus with anti-fibrin MNBs was
demonstrated in circulating blood using a balloon overstretch
injury-induced thrombus formed within the iliac artery of
an atherosclerotic rabbit. For this study, anti-fibrin mAb
was coupled directly to MNB (Bi) particles. Bioelimination
study revealed that 95 % of the metal was cleared in 7 days
and >96 % at 14 days in rodents. This study reports one of
the first examples of targeted Spectral CT molecular imag-
ing demonstrating the potential to detect ruptured plaque
and eliminate calcium interference with CT vascular imag-
ing.
015. AMYLOID HYPOTHESIS FOR AD INSIGHT
FROM SINGLE MOLECULE EXPERIMENTS
AND COMPUTATIONAL ANALYSES
Lyubchenko Y. Department of Pharmaceutical Sciences,
University of Nebraska Medical Center, Omaha, NE 68198.
The current model for the development of Alzheimer’s (AD),
Parkinson’s, Huntington’s, prion, and other neurodegenerative
diseases involves protein misfolding as the early step followed
by spontaneous aggregation, with specific proteins identified
as the primary initiators for disease development. Therefore,
elucidating the properties of the disease-prone misfolded
states, understanding the mechanism of their formation, and
identification of their most toxic forms will open prospects for
the development of early diagnostics and specific therapeutics
for these diseases. We have developed single molecule AFM
force spectroscopy (SMFS) experimental approach enabling
us to probe interprotein interactions and to identify those
interactions that correspond to misfolded protein states. Using
SMFS, we have discovered that misfolded dimers are very
stable. Aß42 and Aß40 are the two primary alloforms of
the amyloid β-protein, and we applied SMFS approaches
to characterize the effects of C-terminal substitutions on
the structure of transiently formed dimers. We discovered a
dramatic difference in the folding patterns of Aß42 and
Aß40 monomers within dimers. Although the sequence
difference between the two peptides is at the C-termini,
the N-terminal segment plays a key role in the peptide
folding in the dimers. To address the question on the
mechanism of the misfolded dimers formation we applied
Molecular Dynamics simulations. When two monomers
approach, their structure changes dramatically. The ar-
rangement of monomers in an antiparallel orientation leads
to the cooperative formation of a ß-sheet conformer. The
amyloid misfolding depends on the environmental condi-
tions and AFM is capable of characterizing these effects.
Partially supported by: NIH 5R01 GM096039-04 and NSF
EPS-1004094
016. NANOMEDICINE IN DEMYELINATING DIS-
EASE: APPLICATION TO DIAGNOSIS AND THERA-
PY IN NEUROINFLAMMATORY DISORDERS
Jacobson S. National Institute of Neurological Disorders and
Stroke, Bethesda, MD 20892.
Multiple sclerosis (MS) is the most prevalent inflammatory,
demyelinating disease of the CNS. Lesions within myelinated
regions of the CNS, mediated by infiltrating T cells are a
hallmark of the disease and lead to progressive neurologic
dysfunction. While the etiological agent(s) of MS remains
unknown, the heterogeneous disease course suggests a host
of complex interactions between immunologic, genetic and
environmental factors. Similar to other inflammatory diseases,
the pathogenesis of a rare, human retrovirus (HTLV-I) associ-
ated neurologic disorder has been suggested to involve inter-
play between host genes and antigen-specific immune re-
sponses. HTLV-I-associated myelopathy/tropical spastic
paraparesis (HAM/TSP) is clinically similar to the chronic
progressive form of MS. It is likely that a more complete
understanding of the pathogenesis of a neurologic disease
with a known viral etiology (HAM/TSP) will aid in defining
mechanisms of pathogenesis of MS, a disease of unknown
etiology in which viruses have been suspected to play a role.
Clinical, pathological, and immunological events in HAM/
TSP have been studied. While progress has been made in
characterizing the role of cellular immune responses to
HTLV-I in HAM/TSP, there remains a significant gap in
knowledge about the inflammatory pathways that are altered,
and how HTLV-I contributes to this dysregulation. Our ability
to translate knowledge gained from these basic virologic/
immunologic studies into clinically effective treatments rep-
resents a unique opportunity to better understand how virally-
triggered immune dysregulation leads to neurologic disease.
As the past decade has seen rapid advances in the integration
of nanotechnology and medicine, there is a compelling need
for the application of ‘nanomedicine’ to the diagnosis and
treatment of inflammatory disorders of the nervous system.
Examples will be highlighted from our studies on HAM/TSP
and MS that will focus on the detection of virus and virus-
specific immune responses in the CNS. In addition, imaging
of these diseases have led to a better understanding of the
pathogenesis of these disorders. The potential for nanoparti-
cles to ferry drugs and contrast agents across the BBB will
likely facilitate more efficacious and precise drug delivery and
disease assessment by MRI.
Supported by: Intramural Program of the NINDS, NIH
017. MR STUDIES TO ASSESS HIV-ASSOCIATED
BRAIN INJURY CURRENT AND FUTURE
PERSPECTIVES
Chang L and Ernst T. John A. Burns School of Medicine,
University of Hawaii at Manoa, Honolulu, Hawaii 96821.
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Despite effective viral suppression with antiretroviral ther-
apy, 30–50 % of HIV patients continue to show HIV-
associated neurocognitive disorders (HAND) and evi-
dence of ongoing neuroinflammation. HAND is often
difficult to diagnose in the clinical settings, and will
become more prevalent due to the aging population. Bet-
ter clinical diagnostic tools are needed. A variety of MR
techniques can evaluate the brain changes. Quantitative
MRI consistently found atrophy in subcortical brain re-
gions in HIV patients with or without HAND. Proton MR
spectroscopy demonstrated ongoing neuroinflammation,
and functional MRI studies showed lower cognitive re-
serve in HIV patients. These brain measures are typically
related to the severity of cognitive deficits. Furthermore,
particular genetic variants (e.g., APOE or COMT) in HIV-
infected individuals are associated with greater brain at-
rophy or greater age-dependent decline in brain function.
Hence, genetic markers and neuroimaging measures may
provide useful endophenotypes to identify HIV patients at
risk for HAND or predict treatment outcomes.
Novel MR contrast agents such as superparamagnetic iron
oxide (SPIO), comprising nano-sized iron oxide crystals coat-
ed with dextran or carboxydextran (60–180 nm), can evaluate
macrophage activities associated with neuroinflammation
(e.g., in patients with ischemic strokes, multiple sclerosis
and carotid plaques). Therefore, these agents may be useful
for assessing neuroinflammation associated with HIV. Fur-
thermore, the distribution of nanomedicine (e.g., SMART)
or cell-based therapies in target organs, including the brain,
can be assessed quantitatively and qualitatively when com-
bined with SPIO agents. These nano-sized contrast agents are
also ideal for translational studies for medication develop-
ment. These emerging applications of SPIO and other poten-
tial new approaches to assess HIV-associated brain injury will
be discussed.
Supported by: NIH (NIDA, NINDS, NIMH, NIMHD)
018. ELECTRON CRYO-TOMOGRAPHY OF CELLS
AND PROTEIN AGGREGATES
ChiuW. National Center forMacromolecular Imaging, Baylor
College of Medicine, Houston, TX 77030.
Electron cryo-tomography (Cryo-ET) has become a critical
structural tool that brings structural insights that cannot be
obtained by crystallography or single particle electron cryo-
microscopy. The advance in instrumentation has made record-
ing tilt series from ice-embedded specimens without chemical
fixative and metal stain relatively routine using a transmission
electron microscope equipped with a cryo-specimen holder
kept at liquid nitrogen temperature. The reconstructed 3-D
tomogram reveals vast amount of sub-cellular features in the
crowded cells or biochemically prepared protein aggregates.
The technical challenges are to annotate the observed
structural features from the 3-D tomograms and to quantify
them. Two examples will be presented to demonstrate how
cryo-ET followed by extensive data processing can yield
mechanistic insights in a biochemical phenomenon of
inhibiting protein aggregation by a chaperonin and the spatial
organization of the subcellular components in the rat hippo-
campal neurite grown on an electron microscope grid.
SESSION 4: NANOTHERAPEUTICS
019. TARGETED POLYMERIC NANOPARTICLES
FROM DISCOVERY TO CLINICALTRIALS
Farokhzad O. Brigham&Women’s Hospital/Harvard Medical
School, Boston MA 02115.
Avariety of organic and inorganic materials have been utilized
to generate nanoparticles for drug delivery applications. The
goal of this talk is to review our efforts in the design and
optimization of polymeric nanoparticles for medical applica-
tions, which formed the foundation for the clinical translation
of the first-in-human targeted and controlled-release nanopar-
ticles, BIND-014 and SEL-068.
020. SCANNING PROBE TECHNOLOGIES FOR
CAROTID MICROTHOMBUS DIAGNOSES USING
SPECTRAL CT
Schmieder A, Pan D, Schirra C, Cui G, Senpan A, Zhang H,
Yang X, ScottM, Allen J,Wickline S, LanzaGM.Washington
University Medical School and Philips Healthcare, St. Louis,
MO 63108.
Since the early work of Benson and Constantinides the acute
formation of thrombus following atherosclerotic plaque rup-
ture has been well recognized as the etiology of unstable
angina, myocardial infarction, transient ischemic attacks and
stroke. The most common source of thromboembolism are
rupturing vulnerable plaques that reside in vessels with only
40 to 60 % residual stenosis. Recent guideline changes have
encouraged that asymptomatic patients with >60 % ipsilateral
stenosis and<3 % surgical risk undergo carotid endarterecto-
my (CEA) as a class A indication. Individuals with higher
surgical risks (e.g., 3 % to 5%), or less stenosis (40% to 60%)
even with suspected ulcerations, are contraindicated for inter-
vention because the patients at high risk who would benefit
from prophylactic intervention cannot be identified with fidel-
ity using current imaging techniques. Indeed, stroke cost in the
US continues around $54 billion/year and is climbing.
Nanodiagnostics are highly suited to intravascular thrombus
imaging, particularly for MRI and an emergent modality
SPECTRAL CT. Spectral CT simultaneously acquires and
presents both a traditional CT image and a K-edge contrast
image superimposed, which uniquely differentiates the con-
trast material (e.g., ytterbium, gold, bismuth) from other
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attenuating materials, such as intraplaque calcium. We have
developed and characterized fibrin-specific “soft nanoparti-
cles” comprised of high-density organometallic complexes,
which provide high SPECTRAL CT contrast against in vitro
phantoms and iliac thrombus after intravenous injection and
circulation in vivo (i.e., rabbits). These nanoagents were de-
graded in vivo and the heavy metal complexes bioeliminated
from the body, as opposed to solid hard metal particles that
can remain in the body indefinitely. Spectral CTcould be used
as a limited scan to rapidly evaluate carotid and vertebral
atherosclerotic disease in patient suspected of or at high risk
for embolic stroke.
021. NANOFORMULATED CELL PENETRATING
SURVIVIN MUTANTAND LACTOFERRIN INDUCED
DIFFERENTIATION AND P-GLYCOPROTEIN
M E D I AT E D A N T I - E P I L E P T I C D R U G
RESISTANCE REVERSAL
Kanwar JR1, Sriramoju B1, Neerati P 2, Takkalapally P2,
Kanwar RK1. 1Nanomedicine Laboratory of Immunology
and Molecular Biomedical Research (NLIMBR), School of
Medicine, Faculty of Health, Deakin University, Geelong
Technology Precinct, Pigdons Road, Waurn Ponds, Geelong,
Victoria 3217, Australia; 2Department of Pharmacology,
University College of Pharmaceutical Sciences, Kakatiya
University, Andhra Pradesh, Warangal 506002, India.
In this study, we investigated the differential actions of dom-
inant negative survivin mutant (SurR9-C84A) against the
cancerous SK-N-SH neuroblastoma cell lines and the differ-
entiated SK-N-SH neurons. In both the cases the mutant
protein displayed dual actions where its effects were cytotoxic
towards cancerous cells and proliferative towards the differ-
entiated neurons. In this study, we also investigated the neu-
ronal differentiating actions of native bovine lactoferrin (bLf)
and its iron saturated form (Fe-bLf). Both forms induced
differentiation in the cancerous SK-N-SH neuroblastoma cells
when treated at a concentration lower than the threshold dose
required for anti-cancer activity. This was evident with the
increased expression of neuronal specific differentiating
markers (neurofilament (NF) 68, anti NF 160, anti-NF 200
etc). bLf adopted PI3K signalling predominantly for inducing
differentiation while Fe-bLf showed these effects involving
both PI3K and ERK pathways. However they showed a
common ability in lowering the expression of endogenous
survivin which is highly specific to the actively proliferating
tumor cells. This is explained as lowered endogenous survivin
expression in the SK-N-SH cells has halted their proliferative
ability and induced the preliminary preparative changes re-
quired for differentiation. This phenomenon is in compliance
with the fact that differentiating/differentiated cells lose their
ability to divide and proliferate thus confirming the Lf differ-
entiating effects. In addition, Fe-bLf showed significant in
vitro P-gp inhibitory activity and hence was tested in an in
vivo epileptic model. Epilepsy, one of the common chronic
neurological disorders is characterized by frequent seizures
and convulsions along with severe drug resistance due to the
P-gp involvement. Surprisingly, in our study Fe-bLf signifi-
cantly enhanced the phenytoin accumulation in the brain
thereby its efficacy when given in combination. Thus, bLf
entitles a novel therapeutic protein for treating brain tumors
and neurodegenerative diseases with its differentiating effects
while the P-gp inhibitory effects effects of Fe-bLf are highly
useful in reversing the drug resistance as seen in epilepsy. In
this study, we have also developed a novel PLGA
nanoparticulate formulation to surmount the hurdles associat-
ed with the delivery of SurR9-C84A thus enhancing its effec-
tive therapeutic outcome.
022. CHARACTERIZATION OF NANOPARTICLE
COMPLEMENT INTERACTION
Pham CTN1, Pan D2, Gordon M1, Lanza GM1, Hourcade
DE1. 1Washington University in St. Louis and 2University of
Illinois at Urbana-Champaign.
Nanoparticles offer new options for medical diagnosis and
therapeutics with their capacity to specifically target cells and
tissues with imaging agents and/or drug payloads. The unique
physical aspects of nanoparticles present new challenges for
this promising technology and raise additional safety issues
arising from their interactions with blood borne components.
Unlike small molecules, nanoparticles are subject to the scru-
tiny of host immune surveillance, the complement system in
particular. Studies indicate that nanoparticles often elicit mod-
erate to severe complement activation that may limit their
clinical application. The complement system comprises three
distinct pathways: the classical pathway (CP) is initiated by
antibody:antigen complexes and the lectin pathway (LP) by
polysaccharides; the alternative pathway (AP) functions spon-
taneously at low level and can serve to amplify the CP. Using
parallel in vivomouse models and an in vitro hemolysis-based
assay we sought to define the pathways and key com-
ponents involved in modulating complement interactions
with perfluorocarbon nanoparticles (PFOBs). Our results
indicate that in the mouse antibody-dependent recogni-
tion of certain PFOBs triggers CP activation, which is
then amplified by the AP. To correlate results obtained
in the mouse with the human system we employed a
modified in vitro hemolysis-based assay to analyze
nanoparticle-mediated complement activity in human se-
ra against a panel of PFOBs and to examine variations between
individuals. We found that nanoparticle surface charge/
chemistry/load all contribute to complement activation. We also
found significant variations in nanoparticle:complement interac-
tions in sera derived from individuals of different race, gender,
and age. This dual approach, using in vivo mouse models and
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in vitro hemolysis-based assay, may provide the tools for an in-
depth structure-activity relationship study that will guide the
development of biocompatible nanoparticles.
023. ENDOTHELIAL NANOMEDICINE
Muzykantov V. Department of Pharmacology, PENNSchool of
Medicine, Smilow Translational Research Center, Philadelphia,
PA 10104-5158.
Endothelium lining vascular lumen controls blood flow and
pressure, as well as vascular permeability and transfer of
circulating materials to tissues. Endothelial cells and their
abnormalities play key role in cardiovascular, neurological,
oncological and other disease conditions. They represent a key
tripartite target, victim and barrier of nanomedicine. Drugs
and carriers have no natural affinity to endothelium.
Nanocarriers targeted to molecules expressed on the endothe-
lial luminal surface optimize delivery of cargoes to and across
these cells. We have devised a series of nanocarriers with
diverse geometries (size, shape and plasticity) and affinity to
specific endothelial epitopes. These features control key pa-
rameters of endothelial drug delivery: pharmacokinetics, bind-
ing to selected endothelial cell phenotypes, intracellular ad-
dressing and duration of therapeutic effects. Pathological fac-
tors (abnormal flow, inflammation) also regulate endothelial
targeting and uptake of nanocarriers. Using these nanocarriers
for endothelial delivery of antioxidant and anti-inflammatory
agents provides therapeutic effects unattainable by non-
targeted counterparts, motivating translational efforts in endo-
thelial nanomedicine.
024. 64CU-DOPED NANOPARTICLES FOR IN VIVO
TUMOR IMAGING AND THERAPY
Sun X, Huang X, Chen X. Laboratory of Molecular Imaging
and Nanomedicine, National Institute of Biomedical Imaging
and Bioengineering, National Institutes of Health, Bethesda,
MD 20814.
Construction of self-illuminating semiconducting
nanocrystals, also called quantum dots (QDs), has attracted
much attention recently due to their potential as highly sensi-
tive optical probes for biological imaging applications. Here
we prepared a self-illuminating QD system by doping
positron-emitting radionuclide 64Cu into CdSe/ZnS
core/shell QDs via a cation exchange reaction. The 64Cu-
doped CdSe/ZnS QDs exhibit efficient Cerenkov resonance
energy transfer (CRET). The signal of 64Cu can accurately
reflect the biodistribution of the QDs during the circulation
with no dissociation of 64Cu from the nanoparticles. We also
explored this system for in vivo tumor imaging. This
nanoprobe showed high tumor targeting ability in a U87MG
glioblastoma xenograft model and feasibility for in vivo lu-
minescence imaging of tumor in the absence of excitation
light. The availability of these self-illuminating integrated
QDs provides an accurate and convenient tool for in vivo
tumor imaging and detection.
Similar approach was also applied to label gold nanoparticles
by chemically reducing 64Cu on the surface of Au. This
chelator-free method can be applicable to different Au
nanomaterials regardless of the size, shape and surface coat-
ing. 64Cu integration has excellent stability with no dissocia-
tion of 64Cu from the particles during circulation and thus no
loss of free 64Cu radioactivity into circulation and thus renal
clearance. Compared with traditional 64Cu chelated
nanomaterials, our 64Cu integrated nanomaterials can give
more accurate evaluation of the pharmacokinetics after sys-
temic administration. Using 64Cu labeled RGD peptide con-
jugated Au nanorods (NRs) with absorption wavelength
around 808 nm (Au NR808) as an example, we further dem-
onstrated the feasibility of these agents to target, monitor and
treat tumors. This novel 64Cu labeling strategy will build a
bridge between positron emission tomography (PET) imaging
and therapeutic nanoagents.
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025. NANOTECHNOLOGY APPROACHES FOR
CONTROLLING STEM CELL FATE
Lee KB. Department of Chemistry & Chemical Biology,
Rutgers University, Piscataway, NJ 08854.
This presentation will focus on the interface between
nanomedicine and stem cell biology. Even though it is well-
established that stem cell fate is regulated by interactions that
occur between microenvironmental cues and intrinsic cellular
programs, our understanding of the function of the microen-
vironment and gene expression in stem cells is hampered by
the limitations of conventional methods and the lack of exten-
sive knowledge of multiple regulatory signals. If complex
stem cell behaviors, such as differentiation and proliferation,
are to be fully investigated, both approaches from nanotech-
nology—the “top-down” patterning of extracellular matrix
(ECM) and signal molecules (e.g. ECM compositions,
nanotopography, pattern geometry, and pattern density),
and the “bottom-up” synthesis of multifunctional nano-
particles and their surface modification with specific sig-
nal molecules—should be combined synergistically. To
address the aforementioned challenges, our research main-
ly focuses on two approaches: i) the development of
combinatorial arrays of microenvironmental signal mole-
cules for the investigation of stem cell behaviors; and ii)
the synthesis and utilization of multifunctional nanoparti-
cles as drug (e.g. small molecules or siRNA) and gene
delivery vehicles to manipulate the expression of key
genes in stem cells.
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More specifically, we have applied combinatorial signal ar-
rays to study the temporal/spatial effect of microenvironmen-
tal cues on adhesion, growth, and differentiation of neural
stem cells. Furthermore, novel multifunctional magnetic
nanoparticles were synthesized and utilized to deliver genetic
materials (e.g. siRNA and plasma DNA) into stem cells and
for multimodal imaging for controlling their neuro-
differentiation pathways. In this presentation, a summary of
the most updated results from these efforts and future direc-
tions will be discussed.
026. CELL-TOPOGRAPHY INTERACTIONS AND
NEURONAL DIFFERENTIATION
Kulangara K, Adler AF, Grigsby CL, Yim EKF, Leong KW.
Department of Biomedical Engineering, and Surgery, Duke
University, Durham, NC 27705.
Topography of extracellular microenvironment can influence
cellular responses from attachment and migration to differen-
tiation and production of new tissue. Cells in their natural
environment interact with extracellular matrix that contains
structures in the nanometer scale. Nanoscaled topography of
synthetic materials, through its resemblance to in vivo sur-
roundings, may provide potent cues to influence the pheno-
types of cells seeded on these nanostructured biomaterials.
This presentation will highlight our recent work on under-
standing the mechanism of cell-topography interactions and
exploiting these interactions for modulating direct cellular
reprogramming.
027. NEUROPROTECTIVE REGULATORY T CELLS
AS VEHICLES FOR NANOFORMULATED GROWTH
FACTOR DELIVERY FOLLOWING TRAUMATIC
BRAIN INJURY
Kelso M1, Elliott BE2, Gendelman HE2. 1 College of Phar-
macy, Pharmacy Practice and 2Department of Pharmacology
and Experimental Neuroscience, University of Nebraska
Medical Center, Omaha, NE 68198.
Traumatic brain injury (TBI) affects neural cells and cerebral
vasculature integrity leading to progressive neurodegenera-
tion. The innate and adaptive immune systems respond to
such injury leading to facilitated damage and repair. The
balance between T effector (Teff) and regulatory T cell
(Treg) functions can regulate neuroinflammatory responses
at sites of tissue damage. Here, Teff accelerate while Treg
restrict continued tissue damage. These actions suggest that
Tregs may be harnessed to positively affect disease outcomes
and for targeted drug delivery. To facilitate a Treg protective
immune response, we subjected C57BL/6 mice to a controlled
cortical impact. The mice were randomized to receive either
granulocyte macrophage colony stimulating factor (GM-CSF;
50 μg/kg), a hematopoietic stem cell factor and known Treg
inducer, or an equal volume of saline 6 h after injury then
continued daily until sacrifice (7 or 14 days). GM-CSF mod-
estly increased splenic Treg populations. Sparing of cortical
tissue was seen after GM-CSF administration with untreated
animals having lesions ~10–15 % larger than treated animals.
Staining for ionized calcium binding adaptor molecule 1, a
microglia marker, was seen at the lesion site as well as the
surrounding regions on days 7 and 14. GM-CSF significantly
decreased staining and appeared to alter microglia morpholo-
gy. Immunoreactivity for glial fibrillary acidic protein, an
astrocyte marker, did not differ amongst treatment groups.
As GM-CSF administration can elicit neuroprotection, we
theorized the Treg could be used as a drug carrier and notably
for vascular endothelial growth factor (VEGF) which shows
angiogenic and neuroprotective properties following TBI.
Therefore, we hypothesized that T cell targeted delivery of a
VEGF complex prepared using anionic block copolymers of
poly(ethylene oxide)-block-poly(L-glutamic acid) could pro-
vide synergistic protection to an injured vasculature and
parenchyma.
Supported by: Carol Swarts Neuroscience Research Labora-
tory, the Frances and Louie Blumkin Foundation, Department
of Defense Grant W81XWH11-1-0700, and National Insti-
tutes of Health grants P20 GM103480, P01 DA028555, R01
NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570
and P01 NS43985.
028. PERSPECTIVE FOR NANOTOXICOLOGY
Toborek M. Department of Biochemistry and Molecular
Biology, University of Miami School of Medicine, Miami,
FL 33136.
Various nanotechnology applications and engineered
nanomaterials (ENMs) have been introduced for treatment,
diagnosis, monitoring, and control of biological systems. How-
ever, surprisingly, remarkably little is known about the health
hazards of ENMs. This lack of knowledge creates a significant
impediment for accurately assessing the risks of ENM expo-
sures and setting exposure standards that are safe for public
health. Potential toxic effects of ENMs are an emerging concern
in medicine and toxicology. The complexity of the ENM sur-
face offers physico-chemical properties that are substantially
different from the bulk material and may contribute to their
toxicity and health risk. These properties are further altered by
surface modifications of ENMs, which occur due to contact
with biological fluids or tissues. We have evidence that binding
of organic pollutants (namely, polychlorinated biphenyls;
PCBs) to seemingly inert silica nanoparticles markedly poten-
tiate vascular toxicity of PCBs. In addition, we evaluated tox-
icity of nanoalumina, which is among the most abundant
chemicals produced as nanosized particles, estimated to ac-
count for ~20 % of the world market of ENMs. Treatment of
brain endothelial cells with nanoalumina induced in dose-
J Neuroimmune Pharmacol (2014) 9 (Suppl 1):S1–S38 S17
dependent mitochondrial potential collapse, increased autoph-
agy, and decreased expression of tight junction proteins,
occludin and claudin-5. Systemic treatment with nanoalumina
resulted in early localization to the brain endothelium, followed
by an entry into the brain parenchyma. Nanoalumina readily
accumulated in the brain and was not eliminated from the brain
components, causing disruption of the blood–brain barrier per-
meability and facilitating stroke development. Overall, these
results caution about the nanoneurotoxicity of ENMs, indicat-
ing that they accumulate in the brain andmay induce previously
unforeseen neurotoxic effects.
029 . GENE THERAPY APPROACHES TO
REGENERATING THE OPTIC NERVE
Foldvari M and Alqawlaq S. School of Pharmacy, Waterloo
Institute for Nanotechnology, University of Waterloo,
Waterloo, Canada.
Glaucoma is the second leading cause of blindness with 60.5
million patients worldwide in 2010, a figure that is expected to
increase to 79.6 million by 2020. Gene therapy with neuro-
trophic factors has potential to provide neuropreventative and
neuroregenerative functions for retinal ganglion cells (RGCs).
However, a significant limitation in ophthalmology is the lack
of effective delivery systems to the retina and the optic nerve.
‘Effective’ encompasses several qualitative, quantitative and
safety requirements. These are: 1) efficiency of delivery to the
back of the eye; 2) biocompatibility; 3) targeted function; 4)
prolonged effect; and 5) potentially non-invasive, pain-free
and low-risk administration. Currently, intravitreal and
subretinal injections are used for reaching the RGCs. Ulti-
mately, topical administration to the ocular surface would be
the safest method for gene delivery to the retina, since it is
non-invasive and painless compared to other delivery
methods. We have developed and characterized non-viral
gemini surfactant-phospholipid nanoparticles (GL-NPs) for
intravitreal and topical administration. GL-NPs carrying
Cy5-labeleld plasmid DNA demonstrated distinct trafficking
behaviour and biodisposition within the eye in vivo in mice
after intravitreal or topical application with respect to path-
ways of movement and physicochemical stability. An over-
viewwill be provided on the design and formulation of gemini
NPs as gene carriers, NP toxicity and the identification of
parameters that require deeper understanding to develop suc-
cessful topical gene delivery systems targeting the retina.
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030. CARRIERS THAT BREAK BARRIERS
Batrakova E1, Haney MJ1, Zhao Y1, Harrison EB2, Mahajan
V1,3, Ahmed S2, He Z1, Suresh P2,3, Hingtgen SD1, Klyachko
NL1,5, Mosley RL3, Gendelman HE3, Kabanov AV1,4.
1Eshelman School of Pharmacy, University of North Carolina
at Chapel Hill, Chapel Hill, NC 27599-7362; 2Department of
Pharmaceutical Sciences, Center for Drug Delivery and
Nanomedicine, 3Department of Pharmacology and Experi-
mental Neuroscience, University of NebraskaMedical Center,
Omaha, NE 68198; and 4Deparment of Chemical Enzymolo-
gy, Faculty of Chemistry, M.V. Lomonosov Moscow State
University, Moscow, Russia.
The ability to precisely upregulate genes in inflamed brain
holds great therapeutic promise. Here we report a novel class
of vectors, genetically modified macrophages that carry re-
porter and therapeutic genes to neural cells. Systemic admin-
istration of macrophages transfected ex vivo with a plasmid
DNA (pDNA) encoding a potent antioxidant enzyme, cata-
lase, produced month-long expression levels of catalase in the
brain resulting in three-fold reductions in inflammation and
complete neuroprotection in mouse models of Parkinson’s
disease (PD). This resulted in significant improvements in
motor functions in PD mice. Mechanistic studies revealed that
transfected macrophages secreted extracellular vesicles,
exosomes, packed with catalase genetic material, pDNA and
mRNA, active catalase, and NF-κb a transcription factor
involved in the encoded gene expression. Exosomes efficient-
ly transfer their contents to contiguous neurons resulting in de
novo protein synthesis in target cells. Thus, genetically mod-
ified macrophages serve as a highly efficient system for re-
production, packaging, and targeted gene and drug delivery to
treat inflammatory and neurodegenerative disorders.
031. MITOCHONDRIA AT THE ORIGIN OF OXIDA-
TIVE STRESS
Perry G1,2, Wang X2, Moreira P3, Castellani RJ4, Nunomura
A5, Zhu X2. 1College of Sciences, University of Texas at San
Antonio, San Antonio, TX; 2Case Western Reserve University,
Cleveland, Ohio, 3University of Coimbra, Portugal, 4 University
of Maryland School of Medicine, 5University of Yamanashi,
Japan.
Mitochondria may underlie oxidative stress in Alzheimer dis-
ease (AD) changes since dysfunction is a prominent and early
feature of AD. Recent studies demonstrate that mitochondria
are dynamic organelles that undergo continual fission and
fusion events, which regulate their morphology and distribu-
tion. Morphometry showed a small but significant reduction in
mitochondria number and enlarged size in AD. Levels of the
fission/fusion proteins DLP1, OPA1, Mfn1 and Mfn2C were
significantly decreased in AD, yet levels of Fis1 were signif-
icantly increased. Interestingly, although all these proteins
demonstrate even distribution in the cytoplasm and processes
of pyramidal neurons in age-matched control hippocampus,
they appeared to accumulate in the soma but not in the pro-
cesses of pyramidal neurons in AD hippocampus. Given that
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OPA1, Fis1, and Mfn1/2 are all mitochondrial membrane
proteins, the changes in their distribution to soma in AD
neurons, suggest changes in mitochondria distribution in these
neurons. The expression of fission/fusion proteins was manip-
ulated in M17 cells and primary hippocampal neurons in a
way that mimicked their expression changes in AD. These
manipulations all reduced mitochondrial density in the
cell periphery (M17 cells) or neuronal processes (primary
neurons) which correlated with reduced spine numbers
(primary neurons).
AbetaPP and Abeta caused reduced expression of DLP1 and
OPA1 while increasing expression of Fis1, consistent with our
findings in AD brains. Through time lapse study, we were able
to demonstrate that mitochondria were able to fuse with each
other but at a much slower rate in AbetaPP overexpressing
cells.
Overall, we concluded that AbetaPP, through Abeta produc-
tion impairs mitochondrial fission/fusion balance through reg-
ulation of expression of mitochondria fission and fusion
proteins.
Supported by: NIH, National Institute onMinority Health and
Health Disparities G12MD007591.
032. NANOMEDICINES FOR NEUROPROTECTION
AND NEUROREGENERATION
Mallapragada SK, Sharma A, Zbarska S, Brenza T, Ghasias S,
Anantharam V, Narasimhan B, Sakaguchi D, Kanthasamy A.
Department of Chemical and Biological Engineering, Iowa
State University, Ames, IA 50011-2230.
In many neurodegenerative diseases such as Parkinson’s (PD)
and Alzheimer’s (AD), or with traumatic brain injuries, there
is a progressive loss of structure or function of neurons,
including death of neurons. Mitochondrial dysfunction, oxi-
dative and nitrative stresses have been implicated in number
of neurodegenerative conditions including PD and AD. Mito-
chondrial targeted antioxidants have been recently shown to
protect against Parkinsonian toxicant, methyl-4-
phenylpyridinium (MPP+) -induced production of reactive
oxygen and nitrogen species production and apoptotic cell
death. Herein, we have investigated the ability of biodegrad-
able polyanhydride nanoparticles to enhance the delivery of
mitochondrial targeted antioxidants to protect against MPP+
induced dopaminergic neurotoxicity. The antioxidant utilized
in these studies apocynin was functionalized with a mitochon-
drial targeting ligand to yield mitoapocynin. Using
polyanhydride nanoparticles, we designed a delivery system
for targeted release of mitoapocynin to mitochondria of cells.
The performance of the designed delivery system was evalu-
ated for neuroprotection against MPP+-induced neurotoxic
cell death in both dopaminergic cell lines and mouse primary
neurons. Cellular uptake and intracellular trafficking of the
particles was evaluated. In a parallel approach, nanomedicine-
based strategies can significantly impact peripheral nerve
regeneration as well. Schwann cells, in conjunction with
micropatterned substrates, have been shown to secrete
nerve growth factor and facilitate peripheral nerve regen-
eration. In order to facilitate peripheral nerve regenera-
tion, polymeric conduits with micro/nanopatterns were
fabricated and the transdifferentiation of mesenchymal
stem cells to Schwann-cell like phenotypes was investi-
gated. This talk will therefore highlight the importance of
nanomedicine in both peripheral and central nervous sys-
tem regeneration.
Supported by: US Army Grant No. W81XWH-10-1-0806
033. ULTRASMALL HYBRID INORGANIC NANOPAR-
TICLE PROBES FOR BRAIN TUMOR IMAGING
Bradbury M1, Zanzonico P2, Larson S1, Wiesner U3.
1Department of Radiology and 2Department of Medical
Physics, Sloan Kettering Institute for Cancer Research, New
York, NY 10065; 3Department of Materials Science and
Engineering, Cornell University, Ithaca, NY 14850.
Despite recent advances in imaging probe development for
nanomedicine, the translation of targeted diagnostic platforms
remains challenging. Nanomaterials platforms currently under
evaluation in oncology clinical trials are largely non-targeted
drug delivery vehicles that not typically surface modified for
direct detection by clinical imaging tools. Here we developed
renally-excreted, fluorescent (Cy5 dye) hybrid silica particle
probes (Cornell or C dots) that have been tailored to specific
molecular targets (i.e., integrins) and labeled with radioactive
iodine moieties. This PET-optical particle imaging probe,
which has received FDA investigational new drug application
(IND) approval, may lead to improvements in cancer detec-
tion, staging, and treatment management in humans. Coupled
with PET imaging and analysis tools, complete and quantita-
tively accurate data sets for targeting kinetics, whole body
distributions, and clearance profiles have been acquired in
preclinical tumor models, as well as in early phase first-in-
human trials following intravenous tracer administration.
Findings in humans are consistent with a well-tolerated inor-
ganic particle tracer, which exhibits in vivo stability and
distinctly unique and reproducible pharmacokinetic signatures
defined by renal excretion. The preferential uptake and local-
ization of the probe at sites of integrin-expressing lesions,
including those within the central nervous system, suggest
the potential utility of these targeted C dots in cancer diagnos-
tics. We further show the use of these methods to accurately
estimate the fraction of the injected particle load that accumu-
lates at sites of brain tumors, in addition to monitoring time-
dependent changes in particle uptake. The foregoing informa-
tion can be extended to treatment management settings for
estimating particle dosing requirements in the context of ther-
apeutic interventions.
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034. TARGETING NEURONS WITH CHITOISAN
NANOPARTICLES
Gabriel Lopez-Berestein, MD, University of Texas MD
Anderson Cancer Center, Houston, TX 77030.
Dr. Lopez-Berestein’s research efforts concentrate on the devel-
opment of nanoliposomes and nanoparticles for the delivery of
siRNA to target major signaling pathways. Several of these
targets were identified to play a prominent role in cell growth in
his laboratory. He brought from concept to clinic, seven differ-
ent antimicrobial and antitumor agents. Of those seven, one,
Abelcet, reached the market and the other six continue in
different stages of clinical development. For this presentation,
he will speak on targeting neurons with chitoisan nanoparticles.
035. NANOFIBER AND NANOCARRIER MEDIATED
MODULATION OF CELL MIGRATION FOR NERVE
REPAIR AND BRAIN TUMORTHERAPY
Bellamkonda R. Department of Biomedical Engineering,
Georgia Institute of Technology and Emory School of
Medicine, Atlanta, CA 30332.
Control of cell migration is important for healing of damaged
tissues and on the flip side, cell invasion is at the root of the
challenge that clinicians face in treating brain tumors. In my
laboratory we have been exploring the use of thin film medi-
ated topographical cues to enable efficient and controlled
migration of cells. In the peripheral nerve context, induction
of Schwann cell migration into critically sized nerve gaps
enables bridging of long nerve gaps.
In the context of brain tumors, we are designing novel
nanocarriers that inhibit brain tumor invasion and demonstrate
that controlling tumor invasion renders gliomas vulnerable to
approved chemotherapeutics.
We are also designing devices to control the invasion of brain
tumors along paths that we specify using topographical guidance
of brain tumors in vivo. We demonstrate, for the first time to our
knowledge, that topographical cues presented by thin films en-
able moving a primary tumor from an intracortical region to an
extracortical hydrogel sink where the tumor cells are killed. This
novel approach of bring the tumor to the drug rather than the drug
to the tumor is enabled by our ability to design constructs that
enable controlled, directional migration of invasive brain tumors.
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036. NANOMEDICINE: AN EDITOR’S VIEW
Balogh L. Editor-in-Chief, Nanomedicine NBM (Elsevier).
Nanomedicine and nanobiotechnology are two rapidly emerg-
ing interdisciplinary areas creating novel materials, substances,
and procedures useful for medicine and life sciences in general.
Nanomedicine focuses on the diagnosis, treatment, monitoring
of patients as well as on the prediction and prevention of disease
and has the potential to forever change how patients are diag-
nosed and treated in the next decade. However, all of this is
happening when both medical science and the pharmaceutical
industry are undergoing radical transformations. There are
many challenges for these paradigm-changing fields, especially
in the area of scientific communication and commercialization.
This talk will focus on scientific publishing. This field is also
undergoing dynamic changes, the essential general question
being how to determine value of research before and/or after
making it public, and how to monetize this value. This dis-
cussion has now expanded to the whole society and several
articles have recently appeared in well-known journals
(Science, Nature, The Economist, etc.) questioning the value
and methods of science.
Getting published is crucial for academicians and researchers.
In this talk the speaker will summarize major changes in
business models (traditional, open access, and hybrid), de-
scribe the use of Impact Factor, and introduce the latest
scientific methods used to determine the value of journals,
and explain how these tools may be used correctly to evaluate
individual authors, groups, institutions, and countries. In ad-
dition to comparing leading nanomedicine journals, a Q&A
opportunity will also be provided.
037. NANOMEDICINE AND TOXICOLOGY
Peterson E. Department of Pharmacology/Toxicology,
University of Arkansas for Medical Sciences, Little Rock
AR 72205.
Methamphetamine (METH) and related stimulant abuse is one
of the most significant drug problems in the US and abroad.
There are no FDA approved medications to treat METH addic-
tion. Biologic-based medications such as anti-METHmonoclo-
nal antibodies and their sequence derivatives are showing
promise in preclinical studies. Both a long-acting IgG and
extremely short-acting single chain variable fragment (scFv)
have demonstrated preclinical efficacy. While the scFv has
important advantages over IgG in terms of cost, ease of pro-
duction, and dose, the in vivo half-life is too short to offer long-
term protection fromMETH. Thus, to improve pharmacokinet-
ics and increase binding properties, we conjugated anti-METH
scFvs to dendrimer nanoparticles to generate nanoconjugates
termed dendribodies. The anti-METH dendribodies retain high
affinity METH-binding properties in vitro and in vivo. More-
over, in rat studies we found that conjugating the anti-METH
scFvs to dendrimers resulted in an extension of the serum half-
life from 1.3 h for the scFv to 26 h for the dendribodies. This
represents a 20-fold increase in the duration of action. Thus, the
dendribody design is a potential platform for generating multi-
valent products from antibody fragments that could translate to
medications with customizable pharmacokinetic profiles.
Supported by: NIH, NIDA R01 DA026423
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038. NANOPARTICLE INDUCED ENDOTHELIAL
LEAKINESS MECHANISM AND IMPLICATIONS
TO NANOMEDICINE
Setyawati MI and Leong DT. Department of Chemical and
Biomolecular Engineering, National University of Singapore
117585.
The endothelium is a common tissue that most nanomedicine
would interact with. While it is not usually the target tissue of
action, how nanomaterials interact with the endothelium is an
important factor to consider. We have shown that inorganic
nanomaterials (Ag, Silica, Titanium Dioxide of primary size
15–30 nm) caused endothelial leakiness (both in vitro and
in vivo). The mechanism was that these nanomaterials enter
and bind to VE-cadherin found in the adherens junctions
between endothelial cells and disrupted the junction, leading
to intracellular signaling that led to a leakiness phenotype and
we coined this as Nanoparticle induced endothelial leakiness
(NanoEL) (Setyawati et al. Nature Comms 2013, 4, 1673).We
also showed that cell tension plays a major part in this disrup-
tion and relaxing cell tension with inhibitors greatly reduce the
NanoEL effect in endothelial cells (unpublished data). We
have also worked out nanoparticle centric parameters that
determine NanoEL so that the nanomedicine field can have
design rules to either induce or avoid NanoEL (unpublished
data). The overall impact of NanoEL to nanotechnology
is that it might be the real nanoparticle induced effect
hidden under the guise of the EPR effect (invited per-
spective manuscript in prep).
039. “METABOLIC PHENOTYPING TO FUNCTION-
ALLY CHARACTERIZE BRAIN REGIONS”
Ivanisevic J1, Epstein AA2, Kurczy M1, Benton P1, Boska
MD3, Fox HS2, Gendelman HE2, Siuzdak G1. 1The Scripps
Research Institute, CA 92037; 2Department of Pharmacology
and Experimental Neuroscience, 3Department of Radiology,
University of Nebraska Medical Center, Omaha, NE 68198.
Historically, the studies of brain metabolism and the related
pathological changes are based on targeted analysis of limited
number of metabolites. Here we use mass spectrometry based
untargeted metabolomics to examine the metabolic balance
across different regions of brain in a humanized mouse model.
Liquid Chromatography Mass Spectrometry (LC/MS) and
Nanostructure Imaging Mass Spectrometry (NIMS) revealed
significant variations in water soluble and in lipid brain me-
tabolome between different regions. Differences in abun-
dance were observed for some of the major brain neu-
rotransmitters and characteristic phospholipid metabo-
lites. This study shows that untargeted metabolic profil-
ing can provide a new insight into functional differences
between brain regions, including discovery of unantici-
pated roles of specific metabolites, and localization of
metabolic changes that correlate to neurocognitive dis-
orders.
040. TRANSPORT OF ICAM-1-TARGETED
NANOPARTICLES ACROSS ENDOTHELIAL-
SUBENDOTHELIAL LAYERS AND UPTAKE BY
NEURONS
Hsu J1, Rappaport J1, Muro S 1,2. 1Fischell Department of
Bioengineering and 2Institute for Biosciences andBiotechnology
Research, University of Maryland, College Park, MD 20742.
Systemic drug delivery into the brain is impeded by the
blood–brain barrier (BBB), a lining of endothelial cells (EC)
and subendothelial cells, astrocytes (AC) and pericytes (PC)
that regulates transport between the bloodstream and neuronal
cells (NC) in the brain. Targeting EC surface receptors in-
volved in transcytosis offers an avenue to traverse this barrier.
Intercellular adhesion molecule 1 (ICAM-1), a molecule in-
volved in leukocyte extravasation, can transport ICAM-1-
targeted particles across cell monolayers, but their interactions
with BBB and brain cells have not been tested. We used
fluorescence microscopy and radioisotope tracing to explore
transport of 100 nm polymer particles coated with antibodies
to ICAM-1 (anti-ICAM NP) into and/or across EC, AC, PC,
and NC, cultured as monocultures or endothelial +
subendothelial co-cultures. Under pathological-like condi-
tions, AC and PC expressed ICAM-1, but at lower levels than
EC (78% and 54% of EC). As a result, AC and PC bound and
internalized anti-ICAMNPmainly by the CAM pathway (not
clathrin pits or caveoli), yet, at a lower level than EC: by 1 h,
AC and PC bound 79 and 95 NP/cell vs 200 NP/cell for EC,
and internalized 42 and 43NP/cell vs 110NP/cell for EC. This
suggests that BBB ICAM-1 is more accessible to targeting
from the endothelial side, as required for systemic adminis-
tration, and retention within subendothelial cells may be low,
allowing penetration into the brain. Accordingly, anti-ICAM
NP targeted brain EC 19-fold over IgG NP and 2.3×10^6 NP/
mm^2 were transported across EC monolayers by 5 h. Anti-
ICAM NP transported across the EC lining were taken up by
subendothelial PC or AC in co-cultures, resulting in transport
of 1.2-3.4×10^6 NP/mm^2 across both layers by 5 h. Also,
NC expressed ICAM-1 and supported binding of 130 NP/cell
and uptake of 40 NP/cell by 5 h. Together, these results
suggest that ICAM-1-targeted NP have the potential to im-
prove drug delivery across the BBB and into neurons.
041. SELF-ASSEMBLED LIPID-POLYMER HYBRID
NANOPARTICLES FORTHE SUSTAINED DELIVERY
OF SMALL INTERFERING RNA
Zhu X, Shi J, Farokhzad OC. Laboratory of Nanomedicine
and Biomaterials, Department of Anesthesiology, Brigham
and Women’s Hospital, Harvard Medical School, Boston,
MA 02115.
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RNA interference (RNAi) has shown great potential for the
treatment of various diseases including cancer. Numerous
nanoparticle (NP) platforms, such as lipoplex and polyplex,
have been developed to facilitate the safe and effective deliv-
ery of small interfering RNA (siRNA) – a major hurdle for the
clinical applications of RNAi. Nevertheless, these NP systems
lack the sustained siRNA release property, and thus can only
induce transient gene silencing due to the short lifetime of
siRNA. Therefore, the delivery of siRNA using controlled-
release NPs would be necessary for achieving sustained gene
silencing. Herein, we develop a novel self-assembled lipid-
polymer hybrid NP platform for safe and effective siRNA
delivery in a sustained manner. The hybrid NPs show excel-
lent in vitro knockdown efficacy at low doses of siRNA, and
promising in vivo results for delivering siRNA to xenograft
tumors. More importantly, these NPs can control the release of
siRNA, with the half-release time of~9 days, for sustained
silencing of target gene expression. Results demonstrate that
the expression of target proteins (e.g., Survivin and PHB1)
can be completely silenced in 2 weeks after the cancer cells
were transfected with the NPs for 6 h. As a comparison, the
protein expression is gradually recovered at day 7–14, after
cell transfection with lipo2000-siRNA complexes. Further-
more, this NP platform can be applied to co-deliver chemo-
therapeutics and siRNAs for the synergistic cancer treatment.
We believe that the lipid-polymer hybrid NP platform with the
property of sustained siRNA release could hold potential in
both fundamental studies and clinical applications.
SESSION8:NANOMEDICINEFORHIVERADICATION
IN BRAIN AND OTHER RESERVOIRS
042. SUSTAINED RELEASE FORMULATIONS FOR
HIV THERAPY
Owen A and Rannard S. University of Liverpool, Liverpool
L693GF, UK.
Antiretroviral Therapy involves co-administration of multiple
drugs to simultaneously inhibit viral targets, maximizing in-
hibition of replication while minimizing resistance.
Antiretrovirals also have application in prevention of HIV
infection and pre-exposure prophylaxis (PrEP) strategies have
been investigated for subjects with high risk of acquiring
infection. Several issues can jeopardize efficacy of HIV drugs
and multiple factors contribute to heterogeneity in response to
therapy. Currently available oral formulations necessitate life-
long, daily dosing and suboptimal adherence places patients at
risk of treatment failure and low rates of protection for PrEP.
Broadly, there are two nanotechnology approaches to efficacy
improvement and enhanced formulation of hydrophobic or
poorly soluble drugs. These are a) “nanocarriers” - utilizing
materials science to attach or encapsulate drugs in a transport
vehicle; and b) “nanoparticle-engineering” - forming a particle
dispersion where each sub-micron particle consists of drug.
Nanomilling has been the most successful nanoparticle-
engineering technology commercially, and relies on the for-
mation of solid drug nanoparticles – ie particles made from
drug with no carrier. Recently, nanomilling has generated
sustained release antiretroviral formulations via intramuscular
depot administration. Long-acting parenteral formulations of
S/GSK744 and rilpivirine have been reported, for which plas-
ma concentrations remain above the IC90 for 1–3 months
after dosing. The advent of long-acting formulations has gener-
ated considerable excitement and a recent study of the interests
and attitudes indicated that 84 % of surveyed patients would
definitely or probably try a once monthly nanoformulated anti-
retroviral therapy. These formulations represent extremely
important progress for HIV therapy, and this presenta-
tion will provide an overview of current progress with a
perspective on knowledge gaps and future development
opportunities.
0 4 3 . A NANOPARTICLE APPROACH TO
TARGETING LATENT HIV RESERVOIR
Marsden MD1, Kovochich M1, Buehler DC1, Shen S1, Toso
DB1, Wu X1, Loo JA1, Zhou ZH1, Kickhoefer VA1, Wender
PA2, Rome LH1, Zack JA1. 1David Geffen School of Medi-
cine, University of California, Los Angeles, Los Angeles, CA
90095; 2Stanford University, Stanford CA 94305.
Antiretroviral therapy can reduce HIV viremia to undetectable
levels, but it does not eliminate infection. Rather a small, but
very stable pool of latently infected memory CD4+ T cells
remains, which upon cessation of therapy, rekindles produc-
tive viral infection. Thus to truly cure HIV disease, this
reservoir must be eliminated. Unfortunately, latently infected
Tcells do not generally produce viral proteins and are thus not
killed by the virus infection itself, and are indistinguishable
from uninfected cells by the immune system. One potential
means of eliminating this reservoir is to activate the latent
virus while the patient is on therapy, which would induce viral
gene expression and render the cell susceptible to virus-
mediated or immune-mediated killing. We have previously
shown that protein kinase C (PKC) activators can induce viral
gene expression from latently infected cells, and render these
cells susceptible to targeting with an HIV Env-specific
immunotoxin. However systemic delivery of these activators
would likely result in unwanted side effects. Consequently we
have chosen to pursue a targeted nanoparticle approach, to
deliver activating molecules more specifically to T cell popu-
lations that might be infected. Our previous work established
that the PKC activator bryostatin 1 can be packaged into
liposomes, which can be targeted specifically to CD4 T cells
by incorporating anti-CD4 antibodies onto the surface of the
liposome. To potentially improve this type of strategy, we are
bioengineering natural, self-assembling vault nanoparticles in
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a manner that allows them to reversibly encapsulate lipophilic
compounds, such as bryostatin 1. These particles are able to
activate viral gene expression from latently infected cell lines,
and we are currently assessing the ability of this approach to
activate lymphocytes in vitro and in vivo.
044. NANOTHERAPIES: CURRENT AND FUTURE
CHALLENGES
Schwartz SA1, Mahajan S1, Reynolds JL1, Ravikumar
Aalinkeel1, Nair B1, Dai L1, Mammen M1, Sykes D1, Prasad
P2, Sellito SJ3, Cwiklinski C3. 1Department of Medicine,
Division of Allergy, Immunology, & Rheumatology and
2Institute for Lasers, Photonics and Biophotonics, Department
of Chemistry, University at Buffalo, The State University of
NY, Buffalo, NY 14260; 3Ceno Technologies, Inc. & Small
Matter, LLC, Buffalo, NY 14209.
Our lab has been using nanoparticles to optimize the delivery of
several drugs and biological agents (e.g. siRNA) for the treat-
ment of a variety of diseases.We explored nanotherapy for such
diverse disorders as neuroAIDS, prostate cancer, drug addic-
tion, asthma, food allergies, and neurodegenerative diseases.
Several of our studies using nanoparticles to transport drugs
across the blood–brain barrier (BBB) utilized unique models of
the BBB including a hollow fiber culture system as a 3 dimen-
sional example of the BBB. Our earlier investigations utilized
quantum dots and gold nanoparticles which showed promise as
theranostic agents. However concerns were raised about the
long term retention of these nanoparticles in the body and their
potential toxicities. Other nanoparticles that we evaluated for
clinical application include chitosan, cationic liposomes,
halloysites, and single walled carbon nanotubes. Current ef-
forts are focused on biocompatible and biodegradable,
nanoparticles composed of functionalized, cationic, poly-
lactic acid. We also examined exosomes as cell or tissue
specific, therapeutic delivery systems. This presentation
will describe our studies and some of the hurdles that




Gendelman HE1, McMillan J1, Boska M2, Liu Y2, Poluektova
L1, Gorantla S1, Bronich T3, Alnouti Y3, LiuX1. 1Department of
Pharmacology and Experimental Neuroscience, 2Department of
Radiology, 3College of Pharmacy, Pharmaceutical Science,
University of Nebraska Medical Center, Omaha, NE 68198.
Drug toxicities, patient compliance and limited penetrance into
viral reservoirs have diminished long-term antiretroviral ther-
apy (ART) efficacy. Novel strategies serve to improve ART
delivery to mononuclear phagocytes (MP: monocytes and
tissue macrophages) and CD4+ T lymphocytes to bring drugs
to viral reservoirs. Over the past decade we pioneered the
development of long-acting injectable nanoformulated ART
(nanoART) with superior pharmacokinetics. A “Trojan Horse”
MP carriage of the drug formulations facilitated the develop-
ment of long-lived storage depots, in liver and spleen. Our drug
formulations enable drug transfer to an infected CNS. We are
currently improving nanoART technology to move it to human
use. We maximized viral clearance by developing a range of
antiretroviral nanoformulated drugs. Synthesis of polymer
drugs with attachments of specific ligand coating directed
drugs to specific virus’ target cells and subcellular regions to
optimize antiretroviral activities. We probed directed formula-
tions in rodents using a newly discovered small magnetite ART
(SMART) platform. SMART formulations were synthesized
by crystalline particles and evaluated for drug pharmacokinet-
ics. Histologic and imaging assays evaluated drug toxicities.
Drug polymer formulations were tested for antiretroviral effi-
cacy, immune and neuroprotection in a humanized mouse
model of HIVinfection. Thework improves nanoART towards
the goal of viral eradication.
Supported by: NIH R01 AG043540-01A1, P01 DA028555-
04, R01 NS3439-19 (HEG).
046. APPLICATION OF TARGETED NANO-NRTI
COCKTAILS AGAINST HIV INFECTION IN THE
BRAIN
Vinogradov SV1, Senanayake T1, Lu Y1, Gorantla S2,
Poluektova LY2, Makarov E2, Warren G1, Gerson T1. 1COP
Pharmaceutical Science, 2Department of Pharmacology and
Experimental Neuroscience, University of Nebraska Medical
Center, Omaha, NE 68198.
Nucleoside reverse transcriptase inhibitors (NRTI)-formulated
nanogels are novel potential drugs for antiretroviral therapy
(ART) in the brain. Standard ART is unable to eradicate
infection from virus reservoirs in the brain and often induce
neurologic complications due to the mitochondrial toxicity of
NRTIs. Brain-targeted nano-NRTIs or nanodrug cocktails
were evaluated by ability to suppress HIV-1 infection and
reduce neuronal damage due to the virus-related inflammation
or drug cytotoxicity. Biodegradable cationic nanogels fabri-
cated from PEGylated cholesteryl-polyamines (e.g. e-
polylysine) and loaded with triphosphorylated Didanosine,
Zidovudine, Lamivudine or Abacavir were tested as single
nanodrugs, or nanodrug cocktails similar to therapeutic
Combivir and Trizivir formulations in infected macrophages.
Sustained release of phosphorylated NRTIs does not induce
mitochondrial damage. Neuronal apoptosis and drug-
triggered production of primary neurotoxic intermediates
ROS was visibly reduced after the treatment with nano-
NRTIs. Nanodrugs exhibited 5-14-fold higher anti-HIVactiv-
ity compared to NRTIs and a therapeutic index up to 400.
Additional three to six-fold higher inhibitions were observed
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for dual- and triple-drug nano-NRTI cocktails similar to ther-
apeutic Combivir and Trizivir cocktails, respectively. Nano-
NRTIs modified with selected brain-specific peptides (e.g.
combinatorial brain-binding peptides) demonstrated up to
three times better blood–brain barrier (BBB) permeability
than nanodrugs in an in vitro cellular BBB model. The excel-
lent accumulation in vivo resulted in the substantial 10-fold
inhibition of viral activity in humanized mouse model of HIV-
1 infection in the brain. Significant suppression of HIV-
related brain inflammation was also observed after
2 weeks of nano-NRTI treatment. In conclusion,
nanoformulations of phosphorylated NRTIs represent
new promising, effective, and less neurotoxic alternative
to current antiviral therapeutics.
047 . PHARMACOKINETIC AND IMMUNE-
DYNAMICS OF MULTI-MODAL NANOPARTICLES
FOR HIVAND/ORTB
Reynolds JL, Prasad P, Morse G, Schwartz SA. University at
Buffalo, The State University of New York, Buffalo, NY
14202.
HIV is ranked globally as the deadliest single most infectious
agent, with TB following a close second. An innovative
therapy for these diseases would combine the antimicrobial
effects of current drugs with an augmented innate immune
system to eradicate these pathogens. These pathogens reside
within macrophages and modulate intracellular reactive oxy-
gen and nitrogen species (ROS/RNS) and pro-inflammatory
cytokines. We have designed glucan functionalized chitosan
shell, poly(lactide)co-glycolide core nanoparticles to stimulate
ROS/RNS, pro-inflammatory cytokine secretion, and delivery
of rifampicin (TB drug) and/or Nevirapine (HIV drug) inside a
2D-human alveolar like macrophage (ALM) model. Nanopar-
ticles significantly enhanced ALM secretion of IL-12p70 (2.9-
fold), TNFa; (16-fold) and INFy; (23-fold) compared to con-
trols over 24 h, and doubled ROS/RNS generation over 6 h.
Nanoparticles delivered 4-fold greater rifampicin concentra-
tions into ALM compared to free rifampicin solution. We then
developed a 3D Hollow Fiber Membrane (HFM) Pharmaco-
kinetic (PK)model to determine the PK of these nanoparticles.
This model consisting of an extra-capillary space (ECS) and a
central reservoir physically separated by a semi-permeable
hollow fiber membrane. We demonstrate that nanoparticles
from the central reservoir can transmigrate across the HFM
(0.1 μm pore size) to the ECS. We next investigated a time
course study in which nanoparticles encapsulated with a fluo-
rescent label (FITC), without drug, were administered in the
central reservoir and samples were taken from both the reser-
voir space and the ECS. Results demonstrate the fluores-
cence intensity in the reservoir space decreased while
the intensity increased in the ECS. These data indicate
that these nanoparticles crossed the HFM and validate
the potential of this 3D model for nanoparticle PK
studies. These data demonstrate the feasibility of deliv-




048. ANTIANGIOGENESIS BASED NANOTHERAPY
FOR PROSTATE CANCER
Aalinkeel R1, Nair B1, Chen C2, Prasad PN3, Cheng C2,
Reynolds JL1, Sykes DE1, Mahajan SD1,3, Chadha K4,
Schwartz SA1,3. 1Department ofMedicine, Division of Allergy,
Immunology, and Rheumatology, 2Department of Chemical and
Biological Engineering, 3 Institute for Lasers, Photonics and
Biophotonics, University at Buffalo, The State University of
New York 14203, 4Department of Molecular and Cellular Biol-
ogy, Roswell Park Cancer Institute, Buffalo, NY 14263.
Outcome studies of cancer therapy using angiogenesis inhibi-
tors demonstrated substantial clinical benefits. However there is
still need for improving their overall efficacy. This can be
achieved by facilitating delivery of anti-angiogenesis agents to
specific cells using tumor-targeted nanoparticles. In this study
we validated a novel approach to inhibit angiogenesis by pros-
tate cancer (CaP) cells using a small interfering (si)RNA spe-
cific for interleukin (IL)-8 with a goal to develop a safe,
biodegradable nanotherapy for local and metastatic CaP. We
used allyl-functionalized L-lactide monomers to yield nanopar-
ticles consisting of a polylactic acid (PLA) backbone. PLA has
been previously shown to be biocompatible and biodegradable,
making it an ideal clinical agent for nanotherapy. We com-
plexed our PLA nanoparticles with IL-8 specific siRNA yield-
ing a PLA-IL-8-siRNA nanoplex. These nanoplexes were read-
ily taken up by human PC-3 CaP cells resulting in significant
silencing of IL-8 gene expression and cell death. In vivo
studies were conducted with athymic, nude mice bearing
PC-3 tumors. PLA-IL-8-siRNA nanoplexes were injected
directly into the tumors. Animals were followed prospec-
tively and showed significant regression of tumors com-
pared to untreated controls. Animals treated with PLA-
IL-8-siRNA nanoplexes showed significant knockdown
of IL-8 gene expression in tumor tissues and decreased
levels of angiogenic and anti-apoptotic cytokines (FTF2,
follistatin, GCSF, IL-17A, and IL-6) in serum compared
with untreated controls. Further, imaging of tumors
showed reduced volume and vascularization by PLA-
IL-8-siRNA nanoplex treated tumors both at 79 and
101 days post tumor inoculation consistent with dimin-
ished angiogenesis. Our study establishes proof of con-
cept for using nanoparticles to deliver gene therapy for
the treatment of CaP. Our next studies will use targeted
nanoplexes to treat metastatic human CaP in an animal
model prior to commencing clinical trials
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049. NANOAPPROACH FOR EFFECTIVE BRAIN OF
NATURAL ANTIEPILEPTIC DRUG
Akhter S. Department of Pharmaceutics Utrecht Institute for
Pharmaceutical Sciences (UIPS) Utrecht University,
Universiteitsweg 99. 3584 CG.
Thymoquinone (THQ) is known for its neuroprotective
and anti-convulsant properties in preclinical studies. In
this work describes the improved brain targeting of
Thymoquinone (THQ) via intranasal route using
mucoadhesive nanoemulsion as carrier. THQ loaded
mucoadhesive nanoemulsion was prepared by aqueous
titration technique and in-vitro evaluation for stability
and release. Anti-convulsant efficacy, brain pharmacoki-
netics, biodistribution and safety of the THQ nanofor-
mulation was performed in rabbits model.
050. HYPERINTENSE CORTICAL T1 SIGNAL IN
PROGRESSIVE LEUKOENCEPHALOPATHY
(PML) REFLECTS SEIZURE RISK
Anwar B. University of Oran, Algeria.
Objective: To determine the frequency of hyperintense cortical
T1 signal (HCTS) on MRI in progressive leukoencephalopathy
(PML) patients, its association with seizure risk and immune
reconstitution inflammatory syndrome (IRIS). Background:
PML, caused by JC virus (JCV) affects predominantly white
matter.seizures point to a cortical origin and add to increasing
evidence of gray matter involvement in PML. HCTS is a radio-
logic marker of cortical laminar necrosis.Methods:We reviewed
clinical data including seizure history, presence of IRIS, and
MRI scans from PMl patients evaluated between 2000 and
2012. Cases that were diagnosed by CSF JCV PCR and who
hadMRI images available were included in the analysis (n=45).
Results: Of 45 patients, 16 (35 %) had seizures and 27(61 %)
had HCTS on MRI. Of the 16 PML patients with seizures, 14
(88 %) had HCTS compared to 13/29(44 %) patients without
seizures (p=0.006). Of the 18 patients with IRIS,14(80 %)
had HCTS compared to 13/27(49 %) to those without
IRIS,(p=0.04).HCTS predicted seizures with an odds
ratio(OR) of 8.5(95 % confidence interval(CI) of 1.66–
43.41).Together HCTS and IRIS predicted seizures with
an Or of 9.9(95 % CI of 2.5–39.3;p=0.001).Conclusion:
Seizures are a frequent complication in PML .HCTS is
associated with seizures as well as IRIS.
051. MEMRI REFLECTS HUMAN NEUROPATHOLO-
GY IN MURINE HAND
Bade A1, Gorantla S1, Dash P1, Makarov E1, Poluektova LY1,
Gendelman HE1, Boska MD2, Liu Y2. 1Department of
Pharmacology and Experimental Neuroscience and 2Department
of Radiology, University of Nebraska Medical Center, Omaha,
NE 68198.
Progressive HIV infection commonly leads to cognitive impair-
ments for HIV associated neurocognitive disorders. Our labs
have successfully reproduced the biology, immunology and
virology of HAND in mice. This is timely as, no reliable
diagnostic test for human disease is available and disease
tracking and therapeutic monitoring are not available in animal
models.We believewe have found an answer to this bottleneck.
To this end, we recently developed amanganese enhancedMRI
(MEMRI) method to reflect central nervous system damage
following HIV infection. This is based on the abilities of Mn2+
acting as a calcium analog where it enters into neurons through
calcium channels. Thus, the T1 relaxivity changes, and hence
T1 weighted signal intensity, are quantitatively proportional to
calcium channelMn2+ activities.MEMRIwas used to examine
brains of humanized mice infected by HIV-1. Changes in
MEMRI signal enhancements during HIV-1 infection showed
profound changes inMn2+ accumulation suggesting associated
neural pathology. This was observed in disease affected brain
regions. Multiple linear regression analysis showed changed
MEMRI signal enhancements positively correlated with high
viral loads at study end (r=0.78 p<0.05) and negatively with
peripheral CD4+ T cells (r=-0.437 p<0.05). Quantitative
immunohistological results showed that GFAP reactions corre-
lated positively with signal enhancements in CA1 (r=0.96,
p<0.05), CA3 (r=0.89, p<0.5) and the dentate gyrus (r=
0.95, p<0.05). This was negatively correlated with
synaptophysin in the CA3 (r=-0.98 p=<0.05) and the sensory
regions of cortex (r=-0.87, p=0.05). The abnormal signal
intensity correlated with viral pathology in infected mice
supporting the emergence of behavioral deficits in infected
animals. We conclude MEMRI could be used to investigate
specific neuropathologic aberrations associated with advanced
viral infection and can be used to monitor therapeutic efficacy
to combat neuronal damage in HAND.
Supported by: NIH P01DA028555, R01NS036126,
R01NS34239 (HEG)
052. NEUROPROTECTIVE EFFECT OF BANANA
FLOWER ON A LIPOPOLYSACCHARIDE-INDUCED
ANIMALMODEL OF PARKINSON’S DISEASE
Chen W. Chung Yuan Christian University, Chung Li,
Taiwan, Republic of China.
Lipopolysaccharide (LPS) induces microglial activation to
release a variety of neurotoxic factors, and damaged neurons
may trigger reactive microgliosis, which lead to progressive
dopaminergic neurodegeneration. It has been used to study the
neuroinflammatory process in the pathogenesis of Parkinson’s
disease (PD) and anti-inflammatory therapy for PD treatment.
Here, the unilateral stereotaxic injections of LPS into the
substantia nigra of male rats are performed to establish the
hemiparkinsonian animal model. Banana flower (Musa
Sapientum) has been shown to exhibit antioxidant activity
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and anti-diabetic property. However, the effect of banana flow-
er treatment on neurodegeneration has not been evaluated. The
objective of this study was to evaluate the neuroprotection of
banana flower in LPS PD model. Rotation behavioral studies
showed banana flower attenuated the associatedmotor deficits,
prevented neurodegeneration. Further observation revealed
banana flower pre-treatment significantly ameliorated LPS-
induced elevations of the mRNA expressions of interleukin-1
beta (IL-1β). Our results suggest that banana flower may play
a role in protecting dopaminergic neurons against inflamma-
tory challenge.
053. EVALUATION OF LONG TERM TOXICITY
OF GRAFEX NANOCARBON ASSISTED MICRO-
WAVE THERAPY (NAMT) FOR APPLICATION OF
TARGETING HUMAN PROSTATE TUMOR CELLS
IN NUDE MICE CAUSING CYTOTOXIC THERMAL
ABLATION USING EXTREMELY SHORT CYCLE
MICROWAVE ENERGY AS PRIMARY THERAPY
DeSantis M. State University of New York at Stony Brook,
Stony Brook, NY 11790.
Purpose: Evaluation of long term toxicity using application of
spherical nanocarbon injected into known Human Prostatic
carcinoma to increase absorption of microwave energy, spe-
cifically into tumor cells. This study was selected to evaluate
NAMT can be used as primary treatment and evaluate the
toxic burden of nanocarbon used during treatment. This spe-
cific nanocarbon has demonstrated a range of energy absorp-
tion capabilities. Materials and Methods: 10 Nude nu/nu
isolated mice were injected with DU145 (ATC#HTB-81) 1×
10^7 Human Prostate carcinoma cells introduced into the
dermis and allowed to grow to >1 cm. A control mouse
received no treatment. A control mouse received only an
injection of 292 molar concentration of nanocarbon. Remain-
ing 8 mice received treatment with the microwave and 292
molar nanocarbon. Medwave generators with microwave
probes were used. Nanocarbon and viscous carrier were
injected into the tumors. Short cycle power using 10 watts at
15 s used as baseline settings. Target temperature within the
tumor was 60 ° C. Results: 67 % of the original treated mice
are alive at 18 months with no signs of toxicity or tumor re
growth. Conclusion: Grafex nanocarbon appears to be non-
toxic in this small animal study. NAMT maximizes energy
transfer. Conversion of microwave energy causes thermal
ablation to the cancer cells. This suggests Grafex nanocarbon
causes enhancement of the dielectric properties of the tumor
causing cytotoxic heating. A larger study is under way.
054. DELIVERY OF ANTITUBERCLIN DRUG
NANOPARTICLES TO SPECIFIC MACROPHAGE
SUBCELLULAR COMPARTMENTS FACILITATES
ELIMINATION OF MYCOBACTERIAL INFECTION
Edagwa B, Guo D, Puligujja P, McMillan J, Liu X,
Gendelman HE, Narayanasamy P. University of Nebraska
Medical Center, Omaha, NE 68198.
Mycobacterium tuberculosis (MTB) is the cause of wide-
spread pulmonary, bone, nervous system, skin, eye and other
systemic morbidities. Complex drug regimens underlie an
alarming worldwide increase in infection rates. The needs
for new treatment regimens to improve patient compliance
and speed microbial eradication are surely needed. We posit
that this may be achieved through long-acting, cell and tissue
targeted, nanoformulated MTB medicines. To this end, we
developed a derivatized hydrophobic isoniazid now called
INHP. INHP and rifampin (RIF) were loaded into poly-
lactide-coglycolic acid (PLGA) nanoparticles. Physical and
chemical properties of the drug formulations as well as the
resultant particle cell uptake, retention, viability and antimi-
crobial efficacy were determined in relationship to native
drugs. These nanoformulations displayed enhanced uptake
of 6 and 4 μg of drug/106 cells when compared to 0.1 μg/
106 cells for native drugs. Sustained release of encapsulated
INHP and RIF were detectable in monocyte-derived macro-
phages (MDM) over 15 days whereas native drug was re-
leased within 24 h. Antimicrobial activities as determined in
dose response tests against Mycobacterium smegmatis
showed ~6-fold increases over equivalent concentration of
native drug when both INHP and RIF nanoformulations were
administered together. Endocytic trafficking of the
antimycobacterium nanoparticles and M. smegmatis showed
identical subcellular compartment localization in recycling
and late endosomes. In conclusion, PLGA nanoparticles
encapsulating RIF and INHP significantly improves
drug uptake and retention and antimicrobial activities
from native drugs. Subcellular distribution study of M.
smegmatis and the PLGA nanoformulations show that
the drugs and the mycobacterium are trafficked into
equivalent endocytic compartments. These results high-
light new opportunities for antimicrobial nanomedicines
to simplify and improve the means to affect MTB
eradication.
Supported by: NIH P01DA028555 and R01 A1097550
(HEG)
055. NANOFORMULATED ART ENDOCYTIC
TRAFFICKING FACILITATES HUMAN MONOCYTE-
MACROPHAGE PARTICLE CARRIAGE
Guo D1, Zhang G1, McMillan JM1, Liu X1, Wysocki BJ2,
Wysocki T2, Gendelman HE1. 1Department of Pharmacology
and Experimental Neuroscience, University of Nebraska
Medical Center, Omaha, NE 68198 and 2Computer and
Electronics Engineering Department (CEEN Dept.),
Wireless Research Laboratory, University of Nebraska-
Lincoln, Lincoln, NE 68182.
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Background: Long-acting nanoformulated antiretroviral ther-
apy (nanoART) can improve patient drug adherence, decrease
systemic toxicity and affect sustained viral suppression. This
occurs through its abilities to maintain consistent plasma and
tissue drug levels. Here, monocyte-macrophages serve as
ART carriers. Specific intracellular compartments traffic
nanoART and promote slow drug release. Methods
Nanoatazanavir(nanoATV) was prepared by high-pressure
homogenization with poloxamer 407. Endosomal compart-
ments were isolated from nanoATV treated human
monocyte-derivedmacrophages (MDM) from 0.5 to 48 h then
purified by immunoaffinity chromatography with Rab-
specific antibodies conjugated to magnetic beads. Confocal
microscopy confirmed subcellular nanoATV distribution.
NanoATV distribution into early, recycling and late
endosome/lysosomal fractions were determined by immuno-
fluorescence staining. Mathematical models were developed
by computer assistance programming simulated particle traf-
ficking activities. Results Particle size and zeta-potential was
optimized for particle MDM uptake and storage assays. Par-
ticles were efficiently engulfed by MDM at 53.5 ug/106
MDM after 16 h, which was 1,000 times higher than free-
based drug. Subcellular compartments (Rab 5, 7, 11 and 14)
were separated and the nanoATV concentrations were 5.5, 6.5,
8.3 and 10.6 ug/106 MDM, respectively. With computer assis-
tance, the nanoATVuptake activity was simulated in endocytic
compartments. Confocal imaging showed particle distribution
in a punctate pattern in cytoplasmic and perinuclear regions.
Antiretroviral studies showed reduction in reverse transcriptase
activity by 93 and 77 % with nanoATVand free-based drug on
challenge 14d for late endosomes. Conclusions: The subcellular
locale of the nanoATVand its slow release underlie the devel-
opments of long-term antiretroviral efficacy. Macrophages act
as drug transporters keeping ART nanoparticles stable in late
endosomes for prolonged time periods.
Supported by: NIH P01DA028555, R01NS036126,
R01NS34239 (HEG)
056. CATIONIC/AMPHIPHILIC PEPTIDE/NUCLEIC
ACID COMPLEXES SPECIFICALLY TRAVERSE
CANCER CELL MEMBRANES AND RELEASE
THEIR FUNCTIONAL NUCLEIC ACID CARGO
Gupta K1, Afonin K1, Viard M1, Puri A1, Zakharov A2,
Nicklaus MC2, Schneider J3, Shapiro BA1. 1Basic Re-
search Laboratory, 2Computer–Aided Drug Design,
Chemical Biology Laboratory, 3Peptide Design and Ma-
terials Section, Chemical Biology Laboratory, National
Cancer Institute, National Institutes of Health, Frederick,
MD 21701.
Among non-viral vectors, cell penetrating peptides (CPPs),
which generally contain a stretch of cationic and/or amphipath-
ic peptides of 5–30 amino acids, have received considerable
attention for their ability to transport nucleic acids into cells
both in vitro and in vivo. Recent reports revealed that cancer
cells are anionic due to the overexpression of negatively
charged phosphatidylserine (PS) lipid and high levels of sialic
acid in comparison to normal cells. These characteristics can be
exploited to improve delivery of therapeutic nucleic acid can-
didates. Herein we describe the rational design and synthesis of
cationic/amphiphilic peptides that upon complexing with
nucleic acids form beta-hairpins and impart amphiphilicity to
the peptide/nucleic acid complex. This facilitates the specific
traversal of anionic cancer cell membranes and enhances the
delivery of a variety of nucleic acid structures that control
cellular functions. We have designed a series of peptides con-
taining alternating hydrophobic and polar/positively charged
residues connected by a type II_ turn promoting sequence
VDPPT that forms beta-hairpins and tested them for transfec-
tion and for Green Fluorescent Protein (GFP) gene silencing
efficiency in human breast cancer cells (MDAMB231). The
ability of these peptides to form beta-hairpins upon
complexing with nucleic acids was verified by circular
dichrosim spectroscopy with MAX35 peptides, which showed
beta-hairpin formation in the presence of siRNAs. As an
example, the HPL24 peptides showed significant transfection
of fluorescently labeledRNA/DNA duplexes andwere capable
of delivering siRNA to efficiently silence GFP expression in
the breast cancer cells as revealed by Fluorescence activated
cell sorting (FACS) analysis. However, MAX8V16E, designed
to be a non beta-hairpin forming control peptide, did not show
significant transfection. Also, QSAR was able to predict some
of the characteristics of these peptides.
057. DELIVERY OF GDNF TO THE BRAIN BY
NOVEL NANOVESICLES FOR THE TREATMENT
OF PARKINSON’S DISEASE
Heldman E1,2, Grinberg S1,2, Linder C1,2, Popov M1,2,
Hollander I1,2. (presenter: Rosenbaum S1) 1Lauren Sciences
LLC, NY and 2Ben-Gurion University of the Negev, Israel.
Neurotrophins like GDNF have good potential as therapeutic
agents in Parkinson’s (PD). However, neurotrophins do not
penetrate the BBB and a targeted delivery system is needed to
derive their therapeutic potential. Here we describe optimizedV-
SmartTM vesicles (based on our nanovesicles shown to cross
the BBB and deliver proteins and siRNA) capable of delivering
GDNF to the striatum and the substantia nigra – brain regions
affected in PD. Nanovesicles were formed from synthetic
bolaamphiphiles containing: acetylcholine head groups that en-
able release from the vesicles upon exposure to AChE; targeting
ligand for targeting to dopaminergic neurons; and chitosan
moieties that enable penetration through the BBB.
Carboxyfluorescein-loaded vesicles were added to cultured
cells, then studied by FACS. GDNF-loaded vesicles were ad-
ministered intravenously to mice, which were then perfused
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with PBS at various times after vesicle administration, brains
removed, homogenized or sectioned for histology, and brain
GDNF determined quantitatively by ELISA and localized by
histofluorescence. Vesicles decorated with targeting ligand bind
to cultured cells that express receptor significantly more than
naked vesicles do, whereas no difference is found between
naked and decorated vesicles in cultured cells that do not express
receptor, suggesting that in vivo specific targeting to dopami-
nergic cells would occur. GDNF, encapsulated in vesicles dec-
orated with targeting ligand, was administered intravenously to
mice and found in significant amounts in the brain with prefer-
ential localization in the striatum and substantia nigra – brain
regions rich in dopaminergic cells. V-SmartTM vesicles, opti-
mized for targeted delivery of GDNF, successfully delivered
GDNF into areas of the brain affected by Parkinson’s and, thus,
show great potential for PD therapy. Results of preliminary
efficacy studies in PD animal models will also be presented.
Supported by: The Michael J. Fox Foundation
058. DELIVERY OF TENOFOVIRTO THE BRAIN BY
NOVEL NANO-VESICLES FOR THE TREATMENT
OF NEURO-HIV
Heldman E1,2, Grinberg S1,2, Linder C1,2, Popov M1,2,
Hollander I1,2. (presenter: Rosenbaum S1) 1Lauren Sciences
LLC, NY and 2Ben-Gurion University of the Negev, Israel.
Many AIDS patients, on Highly Active Anti-Retroviral Treat-
ment (HAART), have non-detectable HIV in the blood and,
yet, measurable amounts in the CNS because of poor BBB
penetrability of some HAART drugs, particularly tenofovir.
Persistent HIV reservoirs in the CNS are considered respon-
sible for neurological impairment in AIDS patients. We have
synthesized novel bolaamphiphiles that form stable
monolayer-membrane vesicles, characterized by high encap-
sulation efficiency, penetrability through the BBB and effi-
cient release of the encapsulated material within the brain.
Here we describe optimized V-SmartTM vesicles capable of
delivering tenofovir into the brain to make HAART treatment
more effective. Nanovesicles were formed from various for-
mulations that contain our novel bolaamphiphiles (bolas) and
tenofovir. Tenofovir encapsulation was determined following
the removal of non-encapsulated tenofovir by size-exclusion
chromatography. The vesicle formulation was optimized to
achieve high tenofovir encapsulation and good BBB perme-
ability. Optimized vesicles were administered to mice and at
various times after vesicle administration, brain tenofovir levels
were determined by LC/MS. Optimal vesicle formulations pro-
duced 20–40 % tenofovir encapsulation. Incorporation of
new bolas with chitosan head groups to the formulation
increased significantly the penetration of the vesicles to
the brain. A single injection (iv) of tenofovir-loaded
vesicles (doses 10-fold below toxic levels) resulted in
brain tenofovir concentration of ~6 ug/gm tissue, much
higher than the therapeutic levels of~100 ng/gm, which
is a typical blood level in HAART patients.
Thus, V-SmartTM vesicles, optimized for brain delivery of
tenofovir, successfully delivered therapeutic amounts of the
drug into the brain after a single iv administration. The results
indicate the feasibility of using V-SmartTM vesicles for low-
ering viral load in the CNS of HIV patients.
Supported by: The Campbell Foundation
059. CREATION OF SUSTAINED RELEASE
MARAVIROC NANOPARTICLES
Hilaire J, Puligujja P, McMillan J, Liu X, Gendelman HE.
Department of Pharmacology and Experimental Neurosci-
ence, University of Nebraska Medical Center, Omaha, NE
68198.
Maraviroc (MVC; SELZENTRY) is a well-known CCR5 co-
receptor antagonist commonly used as part of combination
antiretroviral therapy (cART). A twice-daily dosing regimen,
limitations in virologic suppressive activity, as well as lack of
specific delivery to sites of viral entry, limits its maximal effica-
cy. On balance, when used with select antiretrovirals its
efficacy is significant and sustained. We sought to over-
come MVC limitations by packaging the drug into
nanoparticles enabling monocyte-macrophage uptake
and delivery. The goal is to create a cell-based drug
depot, which will facilitate particle dissolution and sub-
sequent sustained release of MVC at its action site. To
this end, polymeric lipid-coated (PLGA)-MVC nanopar-
ticles were manufactured. Physicochemical characteris-
tics of nanoformulated MVC, as well as human
monocyte-derived macrophage (MDM) uptake, retention,
release and antiretroviral responses were examined.
MDM treated with nanoformulated MVC (nMVC) or
native MVC for 8 h exhibited intracellular drug levels
of 10.7 and 3.9 ug/106 cells, respectively. Ten days
following nMVC treatment (100 μM) MDM retained
1.06 ug MVC/106 cells while native MVC was unde-
tectable. Antiretroviral activity was determined by reverse
transcriptase (RT) activity and HIV-1p24 antigen expres-
sion in HIV-1 infected MDM. MDM challenged with HIV-
1ADA>15 days after 8 h nMVC treatment exhibited dose
dependent reductions in RT activity. At a concentration of
100 uM, nMVC and native MVC resulted in 95 and 40 %
RT activity reductions compared to untreated infected cells
respectively. These results demonstrate that nMVC creates
a cellular drug depot, which facilitates effective antiretro-
viral efficacy weeks after treatment. To further characterize
nMVC, we are determining the PK profile. Overall, devel-
opment of long acting targeted MVC together with reverse
transcriptase, protease and integrase inhibitors could lead to
improved PK of cART and promote improved drug
adherence.
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Supported by: NIH P01DA028555, R01NS036126,
R01NS34239 (HEG)
060. ENDOCYTOSIS PATHWAYS OF THE FOLATE
TETHERED STAR-SHAPED PEG-PCL MICELLES
IN CANCER CELL LINES
Hsieh M-F. Department of Biomedical Engineering, Chung
Yuan Christian University, Taiwan 32023, R.O.C.
This study reports on the cellular uptake of folate tethered
micelles using a branched skeleton of poly(ethylene glycol)
and poly(&#949;-caprolactone). The chemical structures of
the copolymers were characterized by proton nuclear magnet-
ic resonance spectroscopy, and Fourier transform infrared
spectroscopy. Doxorubicin (DOX) was utilized as an antican-
cer drug. The highest drug loading efficiencies of DOX in the
folate decorated micelle (DMCF) and folate-free micelle
(DMC) were found to be 88.5 % and 88.2 %, respectively,
depending on the segment length of the poly(&#949;-
caprolactone) in the copolymers. A comparison of fluores-
cent microscopic images of the endocytosis pathway in
two cells lines, human breast cancer cells (MCF-7) and
human oral cavity carcinoma cells (KB), revealed that the
micelles were engulfed by KB and MCF-7 cells follow-
ing in vitro incubation for 1 h. Flow cytometric analysis
revealed that free folic acid can inhibit the uptake of
DOX loaded in the micelles by 48–57 % and 26–39 %
in KB cells and MCF-7 cells, respectively. These results
prove that KB cells are relatively sensitive to folate-
tethered micelles. Upon the administering of methyl-
beta-cyclodextrin, an inhibitor of the caveolae-mediated
endocytosis pathway, the uptake of DOX by KB cells
was reduced by 69 % and that by MCF-7 cells was
reduced by 56 %. This finding suggests that DMCF
enters cells via multiple pathways, so folate receptor is
not the only target of tumor therapeutics.
061. HAPAND GENOTOXICITY BUDDING TOWARDS
NANOMEDICINE
Huang Y1,2, Yamauchi Y3,4,5, Rawat A1. 1Department of
Bioenvironmental Engineering and Research Center for
Analysis and Identification, 2Center of Biomedical Technology
(CBT), Chung Yuan Christian University, No. 200, Chung-Pei
Road, Jhong-Li 32023, Taiwan; 3World Premier International
Research Center for Materials Nanoarchitectonics, National
Institute for Materials Science (NIMS), 1-1 Namiki, Tsukuba,
Ibaraki 305-0044, Japan; 4Faculty of Science and Engineering,
Waseda University, 3-4-1 Okubo, Shinjuku, Tokyo 169-8555,
Japan; 5PRESTO, Japan Science and Technology Agency
(JST), 4-1-8, Honcho, Kawaguchi, Saitama 332-0012, Japan.
Engineered silver nanomaterials have been touted as panacea
in nanomedicine sector. Nanocomposite materials, such as
Hydroxyapatite (HAP: Ca10(PO4)6(OH)2) and the nano-
hydroxyapatite particles ensures biocompatibility, and used
for dental fillings, implant coatings and bone substitutes.
The reaction mechanism between these material and microor-
ganism still remains obscure; we attempted to perceive it
through a stable reference gene for evaluating the antibacterial
activity of HAP. The minimum inhibitory concentration
(MIC) and half maximal inhibitory concentration (IC50) tests
were conducted with Escherichia coli strain TOP10 treated
metal-coated HAP. The results manifest that the biomaterial
has high surface area and uniform size distribution. The in-
clusion of metal with HAP, like gold and silver imparted them
greater toxicity, than regular non-coated ones. MIC test
confirmed that silver was more toxic than gold. To get
an insight of mechanism, we scrutinized six genes
namely, DNA polymerase I (polA), DNA polymerase
II (polB), cytochrome d complex (cyd), glucan biosyn-
thesis protein G (mdoG), D-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), and 16S ribosomal RNA (16S
rRNA), and performed quantitative reverse transcription
polymerase chain reaction (qRT-PCR) for a complete
gene expression analysis. The expressions of cyd and
mdoG were inhibited, illustrating that the antibacterial
activity of HANPs is related to cell membrane or cell
wall proteins. This study explicitly shows the mecha-
nism of cellular organism with HAP. Attributes like
biocompatibility and genotoxicity can serve as a refer-
ence in synthesis of novel nanocomposite biomaterials
or potentially biomedicines. Nanomedicines currently
hold a tiny niche in pharmaceutical industry, but recent
accomplishments in genetic level has certainly opened
doors for this stream to excel.
062. NANOCONJUGATES OFAGONISTS AND ANTA
GONISTS OF G PROTEIN-COUPLED RECEPTORS
POTENT MULTIVALENT LIGANDS OFADENOSINE
AND P2Y RECEPTORS
Jacobson KA, Tosh, DK, Jayasekara, PS. Laboratory of
Bioorganic Chemistry & Molecular Recognit ion
Section National Institute of Diabetes & Digestive & Kidney
Diseases, National Institutes of Health, Bethesda, MD 20892.
Extracellular nucleosides and nucleotides acting at G protein-
coupled receptors (GPCRs) are important biological signaling
molecules. They are of interest as pharmacological probes and
potential therapeutic agents, including anticancer drugs. With
detailed knowledge of structure activity relationships at both
adenosine receptors (ARs) and P2Y receptors for nucleotides,
we designed selective functionalized ligands for synthesis of
multivalent bioactive nanoconjugates, including soluble
PAMAM dendrimer conjugates and solid nanoparticles
(NPs). PAMAM conjugates of A3AR agonists are effica-
cious in cardioprotection models. AuNPs allow the tuning
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of pharmacokinetic and pharmacodynamic properties by
the active or passive targeting of drugs for cancer and
other diseases. We have functionalized AuNPs by tether-
ing specific ligands, nucleoside agonists and xanthine
antagonists, of ARs as models for cell surface interactions
with GPCRs. These strategically-derivatized NPs, espe-
cially agonists of the anti-inflammatory A3AR, retained
high binding affinity as the covalent conjugates. This is
the first prototypical application to gold carriers of small
molecule (nonpeptide) GPCR ligands, including agents
under investigation for the treatment of cancer and inflam-
matory diseases. Strategies for immobilizing A2AAR
agonists (anti-inflammatory activity) have been explored
in nucleoside conjugates of quantum dots for receptor
characterization. The approach of tethering properly
functionalized GPCR ligands to nanocarriers promises
to provide potent new materials for biomedical applica-
tions.
063. ENCAPSULATION OF NEEM NANOEMULSION
FORCONTROLLINGURINARYTRACT INFECTION
CAUSING BACTERIA KLEBSIELLA PNEUMONIAE
Jerobin J, SinghM, Sahni RD, Mukherjee A, Chandrasekaran
N. VIT University, Vellore, India.
Urinary tract infection (UTI) is a common problem in women
than men which affects the urinary tract of human. The Kleb-
siella pneumoniae is a common bacterium which causes uri-
nary tract infection. Most of the antibiotics currently available
are found to be resistance against the UTI causing bacteria,
and a need has arisen for new antibacterial agent. The
nanoemulsion is kinetically stable non toxic lipid droplet
formulated using pharmaceutical ingredients suitable for hu-
man consumption. The neem (Azadirachta indica) is a
medicinal plant which has antibacterial, antifungal, anti-
viral and antimalarial activities. The oil in water neem
nanoemulsion is formulated using neem oil, suitable sur-
factant and Milli Q water at different ratio. The 1:3 ratio
of neem nanoemulsion is found to be stable with a hy-
drodynamic size of 31 nm. The neem nanoemulsion is
almost spherical in shape when examined by TEM. The
formulated and characterized neem nanoemulsion was
encapsulated with suitable polymer. The FTIR and the
controlled release of azadirachtin a biological compound
in neem conf i rmed the encapsula t ion of neem
nanoemulsion. The PEG coated encapsulation of neem
nanoemulsion was found to be effective against the UTI
causing bacteria K.pneumoniae (MTCC No: 432) by al-
tering the morphology of the bacteria in vitro. The neem
nanoemulsion can be used as an effective antibacterial
agent. More in vivo studies have to be done regarding
the antibacterial activity of neem nanoemulsion against
the UTI causing bacteria.
064. A NANOCOMPLEX CROSSES THE BLOOD-
BRAIN BARRIER AND DELIVERS TO DEEP BRAIN
FOLLOWING SYSTEMIC ADMINISTRATION
Kim S-S1, Garrido-Sanabria ER2, Rait A1, Pirollo KF1, Chang
EH1,3. 1Department of Oncology, Lombardi Comprehensive
Cancer Center, Georgetown University Medical Center,
Washington, DC 20057, 2Department of Biomedicine,
University of Texas Brownsville, Brownsville, TX 78520,
3SynerGene Therapeutics, Inc., Potomac, MD 20854.
Despite major breakthroughs in molecular pathogenesis and
CNS drug discoveries, the inability of free drugs to efficiently
cross the blood-brain barrier (BBB) has been a major imped-
iment in the treatment of neurological disorders including
brain tumors. Thus, there is a critical need to develop new
technologies to meet the challenge. We have developed a
targeted nanodelivery system (scL) for CNS drug delivery
wherein the payload is encapsulated within a cationic lipo-
some. The surface of the liposome is decorated with an anti-
transferrin receptor (TfR) single-chain antibody fragment
(TfRscFv) as a targeting moiety. This rational design allows
the systemically administered scL nanocomplex to take ad-
vantage of the elevated TfR levels present on the cerebral
endothelium of the BBB in order to facilitate its transcytosis
across the BBB. In vivo studies were performed to assess
delivery to the brain of scL after intravenous (tail vein) injec-
tion. The scL nanocomplex was shown to deliver a
fluorescence-labeled oligonucleotide (Cy5-ODN) to the deep
brain, resulting in an accumulation of strong fluorescence
signal in specific regions of the mouse brain including hippo-
campus and cerebellum. Furthermore, tail vein injection of the
scL nanocomplex carrying plasmid DNA encoding the EGFP
protein also resulted in specific expression of exogenous
EGFP in neuronal cells in the deep brain. This scL is a
platform technology, and this nanocomplex has been
shown to be capable of systemically delivering various
payloads including nucleic acid-based therapeutics (plas-
mid DNA, si/miRNA, antisense ODN), diagnostic imag-
ing probes, small molecules and chemotherapeutic
agents to the target tissues. Thus, scL nanodelivery system
provides an efficient and less invasive approach for the deliv-
ery of therapeutic and diagnostic molecules across the BBB.
We believe that this approach has a significant potential for
impacting future treatment of CNS disorders.
065. TUNABLE RESISTIVE PULSE SENSING HIGH
RESOLUTION SIZE, CHARGE AND CONCENTRA
T I O N MEA S UR EMEN T S F OR TAK I NG
NANOMEDICINES FROMTHELABTOTHECLINIC
Kozak D1, Anderson W2, Vogel R3, Broom MF3. 1Izon
Science US Ltd, Cambridge, MA, 2The University of
Queensland, Brisbane, QLD, Australia. 3Izon Science Ltd,
Christchurch, New Zealand.
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Accurate high resolution characterization of complex sys-
tems such as drug delivery particles, viruses, and
microvesicles is critical to understanding their function
and optimization in diagnostic and therapeutic applications.
Tunable resistive pulse sensors (TRPS), such as the Izon
qNano and qViro-X, have generated considerable interest
for their ability to accurately characterize the size, charge
and concentration of nano to micro-scale particulate sus-
pensions. Measuring the properties of each particle (e.g.
liposome, exosome, virus, microvesicle, or cell) as is
passes through the elastic pore sensor provides high reso-
lution analysis often beyond that of other analysis tech-
niques. Furthermore, the recently developed capability to
simultaneously measure the size and charge on a particle-
by-particle basis provides a unique method to better char-
acterize and understand the role that these properties play.
We present the fundamental principles behind TRPS and
demonstrate how it has been used to improve the charac-
terization of particle size, charge and concentration within
complex (e.g. polydisperse or multimodal size and charge)
suspensions. The ability to easily resolve similar but dif-
ferent sized particle populations has been demonstrated
on biological and model complex samples composed of
particles with diameters of 220, 330 and 410 nm.
Tuning the sensor gave rise to a 6 fold improvement
in the measurement sensitivity and when compared to
four other size analysis techniques, TRPS was one of
two devices capable of accurately resolving particles
within complex samples. These instruments have been
used to characterize a wide range of synthetic and biological
particle systems including adenovirus, exosomes, DNA
coated particles, Baculovirus occlusion bodies, and
Prochlorococcus as well as study the surface modification,
aggregation, and storage effects on liposomes.
066. A FOLATE USPIO MRI SCREEN FOR PHARMA-
COKINETIC ASSESSMENTS
Li T1, Gendelman HE1, McMillan JM1, Liu X1, BoskaMD1,2.
1Department of Pharmacology and Experimental Neurosci-
ence and 2Department of Radiology University of Nebraska
Medical Center, Omaha, NE, 68198.
Background: Alendronate (ALN) is a bisphosphonate deriva-
tive with strong metal-chelating properties. In this report, we
successfully harnessed ALN-conjugated polymers and coated
them onto ultra-small superparamagnetic iron oxide (USPIO)
particles (APM). This served to generate a hydrophilic mag-
netite particle of<20 nm. A folate-ALN polymer (FAP) was
synthesized to make FAP coated USPIO particles (FAPM) in
order to facilitate macrophage targeting for cell-guided tissue
particle delivery. Our overarching goal is to use FAPM to
investigate targeted antiretroviral nanoparticle (nanoART) de-
livery to sites of human immunodeficiency virus (HIV)
infection. Methods: ALN-conjugated methoxy poly (ethylene
oxide), ALN-PEO, was synthesized by click chemistry. The
stability of the APM was evaluated with divergent buffers pH
(2 - 12) and NaCl salts (0 – 2 M). The magnetic resonance
(MR) T2-weighted relaxivity was determined. Results: ALN-
PEO coating onto USPIO is rapid, efficient, stable and tun-
able. Up to 100 % of the polymer coated onto USPIO was
seen at a 10 to 1 weight ratio of ALN-PEO/USPIO. The
coating was stable in pH 2 to 12 buffers and up to 2 M NaCl
salt solutions. There was no significant increase in size and
polydispersity of USPIO in buffer and NaCl solutions over
1 month of storage. MR relaxivity studies showed that APM
has the similar T2-weighted relaxivity constant to that of
Ferumoxytol (81.50 versus 83.92, s-1 mM-1). In animals
stimulated with lipopolysaccharide, FAPM showed more ac-
cumulation in various tissues compared to nontargeted parti-
cles (0.25vs0 ug/mL for renal pelvis, 0.65vs0 ug/mL for renal
cortex, 1.34vs0.26 ug/mL for spleen and 3.36vs1.36 ug/mL
for liver, respectively). Conclusions: We posit that the USPIO
coated with ALN-PEO is stable, tunable and non-cytotoxic,
permitting its further development in multimodal USPIO-
based theranostics. By targeting activated macrophages,
FAPM demonstrate the potential for assessing image-guided
drug pharmacokinetics.
Supported by: NIH P01DA028555, R01NS036126,
R01NS34239 (HEG)
067 . THE MOTION CONTROL OF FE3O4
NANOMATERIAL AND ITS APPLICATIONS IN
NANOMEDICINE
Liu D, Gabayno JL, Chang M. Chung Yuan Christian
University, Chung Li, Taoyuan, Taiwan.
In this paper, we report controlled motion of magnetic
nano/micro materials (Fe3O4) which are remotely driven to
assemble, rotate, and propel in suspension by oscillating mag-
netic fields. The propulsion of the nanomaterials is guided
directly by an array of permanent magnets and a solenoid
connected to an AC source. The magnetic field induction in
the immediate vicinity of the sample is controlled by varying
the current and frequency of the oscillating field. Optical in-
spection using a high speed camera tracks the motion of the
nano/microstructures.
In the suspension, the nanomaterials assemble into ellipsoidal
microstructures. These are magnetized by the permanent mag-
nets to align the magnetic moments along with the field. The
oscillating field creates the torque on the microstructures to
create rotation about its long axis. A strong static field is also
applied to generate a high gradient magnetic field. This gra-
dient produces the thrust to propel the microstructures. The
length and diameter of the structures are also controlled by the
static field. For structures 10 μm in length and 1 micrimeter in
diameter, the onset of spiral motion is observed if the
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oscillating field amplitude is 5 gauss. Translation is initiated at
10 gauss and the field gradient is 0.0286 T/m. At 20 gauss and
field gradient of 0.0454 T/m, the rotational and linear speeds
are 47.1 rad/s and 15.4 µm/s, respectively.
From the above results, we demonstrate the capability of the
system by translating the microstructures to a target area and
switch on the oscillating field to produce rotation. This controlled
motion is applied for the fast removal of thrombus. This shows
that non-toxic, cost-effective, and batch-produced nanomaterials
can be tailored to behave in a controllable fashion as scalable
nano/micro motors. Its application for mixing non-
magnetic carrier agents in blood is also being explored.
068. NANOTHERAPEUTIC APPROACH FOR
TARGETING THE HIV RESERVOIR IN THE BRAIN
Mahajan SD1, Yu Y2, Chen C2, Aalinkeel R1, Reynolds JL1,
Nair BB1, Sykes DE1, Mamman M1, Cheng C2, Schwartz
SA1. 1State University of New York at Buffalo, Medicine,
Buffalo, NY 14214 and 2State University of New York at
Buffalo, Chemical and Biological Engineering, Buffalo, NY,
14214.
Background: Nanotechnology can revolutionize the field of
HIV medicine by improving delivery of antiretrovirals to
targeted regions in the body and by significantly enhancing
the efficacy of the currently available antiretroviral medica-
tion. Development of a biocompatible nanoformulation that
can target HIV-1 in sequestered sites requires the use of
functionalized nanoparticles that are engineered to deliver
drugs to specific sites in the body where the virus is seques-
tered, such as the brain. To establish proof of concept, we
choose the protease inhibitor “Atazanavir” which is an antire-
troviral drug with limited Blood Brain Barrier (BBB) perme-
ability. Methodology: We developed a biodegradable
Poly(lactic-co-glycolic acid) - nanoparticles (PLGA-NPs) na-
noformulation of Atazanavir and evaluated its ability to effec-
tively cross the BBB and target specific HIV-1 infected im-
mune cells such as monocytes and macrophages and HIV-1
infected neuronal cells in the brain parenchyma. Further, we
evaluated the efficacy of this nanoformulation in-vitro using a
3 dimensional dynamic in-vitro BBB model (DIV-BBB).
Results: Our confocal imaging results show a significant
increase in uptake of the Atazanavir nanoformulation as
compared to Atazanavir alone by neuronal and immune
cells in-vitro. Additionally, we not only observed a signif-
icant increase in the transversing ability of the nanoformu-
lation across the in-vitro BBB as compared to Atazanavir
alone, but also observed a significant decrease (80 %;
p<0.01) in p24 levels in HIV -1 infected monocytes
treated with the nanoformation as compared to those treat-
ed with Atazanavir alone. Conclusion: Our results suggest
that the nanoformulation can provide sustained release of
the antiretroviral in the CNS, as well as target immune
cells such as HIV-1 infectedmonocytes andmacrophages in the
brain thereby eliminating the sequestered virus from the brain.
069. NANOART INDUCED BIOLOGICAL RE-
SPONSES IN MURINE EXUDATES
Martinez-Skinner A, McMillan J, Gendelman HE. Depart-
ment of Pharmacology and Experimental Neuroscience,
University of Nebraska Medical Center, Omaha, NE 68198.
Eradication of human immunodeficiency virus (HIV) requires
penetrance of long-acting antiretroviral therapy (ART) into
viral reservoirs. We embraced this requirement by the devel-
opment of nanoformulated ART (nanoART). Amongst its
unique properties rests the ability to activate monocyte-
macrophages leading to enhanced cell migratory, phagocytic,
and secretory functions. Although nanoART’s cellular carry-
ing capacities are known in vitro little has been uncovered
in vivo. To this end we assessed cellular temporal uptake of
nanoART in murine peritoneal cell exudates following
nanoART treatment. Here, balb/c mice were injected by the
intraperitoneal route with 100 mg/kg of nanoatazanavir
(nanoATV) and peritoneal exudates collected 4, 12, 24, and
48 h later. Fluorescence-activated cell sorting facilitated stain-
ing for Cd11b, F4/80, and GR-1. Cellular fractions, plasma
and lymph nodes were analyzed by high performance liquid
chromatography for drug. NanoATV induced equivalent cel-
lular responses as was observed by Zymosan A (inflammatory
agent) with the sole exception of the macrophage population.
Surprisingly, macrophages appeared 2 logs below Zymosan A
treatment after 4 h of nanoATV treatment. While macrophage
cell numbers rose at 12 h, they remained lower than controls
without evidence of direct cytotoxicities. NanoATV concen-
trations among sorted cell populations at each of the time
points indicate high specificity of drug particles for macro-
phages independent of cell numbers. Notably, ATV concen-
trations within lymph nodes were significant after 4 h (4 μg/g
tissue) without change after 12, 24, and 48 h. Overall, these
data demonstrate the targeting ability of nanoART and the
biological effects of particle-cell interactions on cell migra-
tion. The results support the idea that macrophages traffic
rapidly after exposure to nanoART and to regional lymph
nodes. Such data further support the promise of nanoART in
its potential to eradicate viral reservoirs.
Supported by: NIH P01DA028555, R01NS036126,
R01NS34239 (HEG)
070. ASSESSING POSSIBLE TOXICOLOGICAL EF-
FECTS OF CARBON NANOPARTICLES ON LIVER
AND KIDNEY OF RATS
Mendonça D1,2, Soares E2, Ceraglioli HJ3, Baranauskas V3;
da Cruz-Höfling MA1,2. 1Department of Pharmacology, Fac-
ulty of Medical Sciences, Zip Code 13083-887, Campinas,
Brazil, 2Department of Histology and Embryology, Institute
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of Biology, State University of Campinas (Unicamp), Zip
Code 13083-863, Campinas, Brazil, 3Department of Semi-
conductors, Instruments and Photonics, School of Electri-
cal and Computer Engineering, State University of Campinas
(Unicamp).
Carbon nanoparticles, such as Graphene oxide (GO), have
emerged as instrumental for biomedical applications and
nanomedicine because of their unique physical, chemical,
electrical, and mechanical properties. In recent years, conflict-
ing data have been reported about possible toxicological im-
plications of carbon nanoparticles in nanomedicine. Herein,
we investigate whether GO nanoparticles dispersed in H2O
and GO dispersed in polyethylene glycol (PEG) (1 mg/ml)
affects the indicators of kidney (urea and creatinine) and liver
(alanine transaminase (ALT) and aspartate transaminase
(AST)) health. GO nanoparticles were administered to 6-
week-old male Wistar rats, (Rattus novergicus) at a dose of
7 mg/kg by intravenous injection into the tail vein (n=3/
group) and kidney and liver parameters examined at different
time intervals (15 min, 1 h, 3 h and 7 days). Statistical analysis
was performed using unpaired Student’s t-test; data were
expressed as mean ± SEM with p ≤ 0.05 indicating signifi-
cance when compared to the corresponding control. The ex-
periment followed COBEA guidelines and was approved by
the University’s Committee for Experimental Use of Animals
(CEUA, protocol 2884-1). The treatment with GO-H2O
caused only an 18 % increase of creatinine at 15 min
(p ≤ 0.05), whereas the hepatic parameters remained normal.
Moreover, the serum level of urea decreased transiently by
40 % at 3 h (p ≤ 0.01) with GO-H2O and the serum levels of
hepatic AST decreased by 64 % after 7 days treatment with
GO-PEG (p ≤ 0.05) indicating improvement of kidney and
hepatic functional parameters. No histopathological changes
were detected in groups. The data demonstrated that carbon
nanoparticles exposure to rats present minimal toxicological
effect at the experimental conditions used.
071. LIPID-BASED VACCINE NANOPARTICLES
FOR INDUCTION OF ROBUST CELLULAR AND HU-
MORAL IMMUNE RESPONSES AGAINST MALARIA
AND HIVANTIGENS
Moon JJ. University of Michigan, Ann Arbor, MI 48109.
There is a great interest in new vaccine technologies that can
elicit robust cellular and humoral immune responses. We have
developed a novel vaccine platform, called interbilayer-
crosslinked multilamellar vesicles (ICMVs), and demonstrat-
ed their efficacy to elicit immune responses against subunit
antigens. ICMVs were formed by fusing liposomes into
multilamellar vesicles and subsequent crosslinking of adjacent
lipid headgroups across lipid bilayers within multilamellar
vesicles (Moon et al. Nat Mat 2011). These nanoparticles
exhibited substantially enhanced protein loading and extended
drug release kinetics compared with traditional drug delivery
vehicles (e.g. liposomes and polymeric particles).
Crosslinking of lipid bilayers enhanced stability of par-
ticles in serum, allowing efficient delivery of antigens to
antigen-presenting cells. ICMVs encapsulating ovalbu-
min and FDA-approved adjuvant elicited potent anti-
body and CD8+ T cell responses in vivo, comparable
to those induced by viral vector vaccines, but without
safety issues and anti-vector immunity associated with
viral vectors. Furthermore, ICMVs carrying a malaria
antigen elicited robust humoral immune responses with
high-avidity antibody titers lasting more than a year
(Moon et al. PNAS 2012). Lastly, we examined ICMVs
as a vaccine carrier for HIV antigens (Li, Moon et al.,
Sci Transl Med 2013). Mice were immunized via pul-
monary route with a gag HIV peptide in ICMVs had
significantly higher frequency of AL-11-specific CD8+
T cells in lungs, lymph nodes, spleen, gut, and repro-
ductive tract, compared with mice immunized with sol-
uble antigens. These results suggest that ICMVs are a
potent vaccine platform that can stably deliver antigen to
lymphoid tissues and elicit significantly enhanced cellular
and humoral immune responses to subunit antigens.
072. A NOVEL NANOBEACON FOR IMAGING CO-
LORECTAL CANCER
Pham W. Vanderbilt University School of Medicine,
Nashville, TN 37232.
Purpose: The objective of this research is to integrate nano-
technology with molecular imaging for early detection of
colorectal cancer (CRC). CRC undergoes a protracted asymp-
tomatic stage before it reaches the advance stage. Therefore,
detection in the early onset through regular screening will
improve therapeutic outcomes and save lives. In that regard,
colonoscopy is considered the golden standard for early de-
tection. However, its effectiveness for early detection of tumor
growth is mitigated by its incapacity to disclose molecular
level changes. One molecule associated with the development
and progress of CRC is the Thomsen-Friedenreich (TF) anti-
gen (Ag). High expression of TF disaccharide in CRC and its
absence from normal tissue represents a unique association in
CRC that exhibits the qualities of a prognostic biomarker.
Method: We developed a fluorescence (FL) nanobeacon,
which can bind specifically to TF-associated CRC due
the presence of multiple identical copies of peanut ag-
glutinin (PNA) molecules derivatized on the surface of
the nanobeacon. The physical property of the FL
nanobeacon such as size, shape, surface topography,
elemental composition and polymer distribution was
evaluated using DLS, SEM, XPS and permeation chro-
matography, respectively. We assessed the sensitivity
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and specificity of the nanobeacon on human specimens.
In addition, we developed an orthotopic rat model of
CRC to assess the specificity of the nanobeacon using
white light and FL colonoscopy. Results: The overall
size of the nanobeacon is approximately 350 nm. There
are approximately 200–300 PNA molecules, which serve
as molecular recognition moieties. In vivo imaging data
demonstrated that the FL colonoscopy using the
nanobeacon detects CRC much earlier than conventional
colonoscopy. Conclusion: We demonstrated the potential
use of a novel nanobeacon for early detection of CRC.
The data suggests that TF Ag can be used as a potential
biomarker for imaging CRC.
073. MACROPHAGE-TARGETED LONG-ACTING
NANOFORMULATED ANTIRETROVIRALTHERAPY
Puligujja P, McMillan J, Balkundi S, Kendrick L, Hilaire J,
Bade A, Gorantla S, Poluektova L, Liu X, Gendelman HE.
Department of Pharmacology and Experimental Neuroscience,
University of Nebraska Medical Center, Omaha, NE 68198.
Background: Patient antiretroviral therapy (ART) adherence,
distribution to viral sanctuaries, antiviral responses and optimal
pharmacokinetic and pharmacodynamics (PK and PD) underlie
the success of drug treatment strategies. To such ends long acting
nanoformulated ART (nanoART) was developed. However,
progress has been hampered by high dose requirements. We
posit that the addition of specific cell targeting ligands, such as
folic acid, on the particle surface will improve treatment out-
comes. Methods: Folic acid-poloxamer 407 (FA-P407) ritonavir
boosted atazanavir (ATV/r) nanoformulations were prepared by
high-pressure homogenization and physicochemical parameters
determined. ATV/r nanoART cell uptake, drug retention, release
and antiretroviral activities were determined in human
monocyte-derived macrophages (MDM). PK and PD were per-
formed in Balb/cJ mice after intramuscular (IM) injections.
Dose-dependent antiretroviral activities were performed in hu-
man peripheral blood lymphocyte reconstituted NOD/scid-IL-
2Rgc (NSG huPBL) mice-infected with HIV-1ADA. Immune
profiles (CD4+/CD8+ Tcell ratios); HIV-1p24 RNA and antigen
were determined in infected spleens. Results: FA coated
nanoART demonstrated>2-fold higher drug uptake, retention
and release in MDM than untargeted formulations. In Balb/cJ
mice, plasma ATV levels were 400 ng/ml and 5-fold higher than
uncoated formulations. Tissue drug levels (liver, kidney, spleen
and lymph) increased from 2-5-fold by FA coatings. Antiretro-
viral activities were dose dependent, with little or no
detectable HIV-1 p24 antigen and HIV-1p24 RNA
14 days following a single IM injection with 50 and
100 mg/kg doses. Folate targeting facilitated drug de-
pots in recycling endosomes. Serum chemistry tests
showed normal metabolic profiles. Conclusions: These
data, taken together, show superior PK and PD and
antiretroviral responses in targeted nanoART formula-
tions demonstrating potential for human use.
Supported by: NIH P01DA028555, R01NS036126,
R01NS34239 (HEG)
074. PROTON BEAM TRIGGERED NANOPARTICLE
DRUG DELIVERY FOR TARGETED CONCURRENT
CHEMORADIOTHERAPY
Ranjan A and Fernando R. Oklahoma State University,
Stillwater, OK 74074.
Purpose: The objectives of this study were to: 1) determine if
mild hyperthermia (40–42 °C) can sensitize tumor cells for
more effective proton beam radiotherapy (PBRT); 2) charac-
terize the survival fraction of cells exposed to PBRT; and 3)
characterize release of the drug doxorubicin (Dox) from low
temperature sensitive liposomes (LTSLs) without exposure to
mild hyperthermia in combination with PBRT. Methods: Dox
was actively loaded in LTSLs. A549 monolayer cells were
incubated with 100–200 nM of Dox-LTSL (± mild hyperther-
mia). Cell irradiation (0–6 Gy) was performed by placing the
cell culture plates inside a solid water phantom and using a
clinical proton treatment beam with energy of 150 MeV. End
points were survival fraction, radiation-mediated Dox release,
and reactive oxygen species (ROS) production. Results: Hyper-
thermia effectively sensitized cells for PBRT and lowered the
cell survival fraction (SF) by an average of 9.5 %. The combi-
nation of 100 nM Dox-LTSL and PBRT (1–6 Gy) achieved
additive to synergistic response at various dose combinations.
At higher radiation doses (> 3 Gy), the SF in the Dox and Dox-
LTSL groups was similar (~20 %), even in the absence of
hyperthermia. In addition, 30 % of the Dox was released from
LTSLs and a 1.5–2 fold increase in ROS level occurred com-
pared to LTSL alone therapy. Conclusion: The combination of
LTSLs and PBRT can achieves additive to synergistic effect at
various dose combinations in vitro. Concurrent PBRTand Dox-
LTSL treatment significantly improved the cytotoxic outcomes
of the treatment compared to PBRT and Dox chemotherapy
without LTSLs. We hypothesize that PBRT may induce drug
delivery from LTSL in the absence of hyperthermia.
075. ROLE OF CARRIER SIZE ON THE TRANSPORT
OF DRUG CARRIERS ACROSS CELLULAR
BARRIERS
Serrano D1, Chadha R2, Muro S2,3. 1Biological Sciences
Graduate Program, 2Institute for Bioscience and Biotechnol-
ogy Research, and 3Fischell Department of Bioengineering,
University of Maryland, College Park, MD 20742.
Transport of drug carriers across cell layers (e.g. for delivery
across the blood-brain barrier) remains a major challenge.
Targeting cell surface receptors involved in vesicular transport
via transcytosis across these linings has shown promise to
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overcome this obstacle. However, how carrier biophysical pa-
rameters affect transcytosis remains unexplored. Since carrier
size impacts rate and mechanism of uptake by cells, we focused
on this parameter. As an example, we examined ICAM-1-
targeted carriers. ICAM-1 is a transmembrane protein involved
leukocyte transit from blood into tissues, and supports transport
of drug carriers across cells via cell adhesion molecule (CAM)-
mediated endocytosis. CAM-uptake differs from clathrin- and
caveolae-mediated endocytosis, allowing for uptake of carriers
of a wide range of sizes (100 nm to several μm in diameter).
This flexibility in uptake makes the CAM-pathway suitable to
study the role of carrier size in transcytosis. We used model
polymer carriers of different sizes coated with antibodies to
ICAM-1 to study transport into and across endothelial mono-
layers. We found that, although increasing carrier size decreased
the number of carriers bound to cells (from 57.3 to 2.2), the cell-
surface area occupied by bound carriers increased with carrier
size (0.45 to 34.6 μm^2). Despite this, efficiency of endocytosis
(% carriers internalized) was high and independent of carrier
size (90 to 95 %). As per intracellular distribution, increasing
carrier size lowered transport to lysosomes (from 85 to 40 %
lysosome colocalization). Surprisingly, yet in agreement with
lower lysosomal transport, increasing carrier size augmented the
efficacy of transport across cells, with micro-carriers exhibiting
higher efficiency of transport than nano-carriers (37.6 vs. 14.2%
transport). These results illustrate the role of carrier size in
modulating transport across cell layers and hold potential to
guide drug delivery across cell linings, e.g. into the brain.
076. SYNTHESIS, CHARACTERIZATION AND
EVALUATIONOFACORE-SHELLNANOCOMPOSITE
AS ORALLY INGESTIBLE MAGNETIC RESONANCE
CONTRASTAGENT
Shanavas A1, Bahadur D2, Srivastava R1. 1BSBE, 2MEMS,
Indian Institute of Technology Bombay, Mumbai, India.
Iron oxide nanoparticles (IONP) are T2 Magnetic Resonance
(MR) contrast agents, when taken orally are limited to gastro-
intestinal (GI) imaging [1].While the available reports warrant
them as safe contrast agents via intravenous route, at least one
report has shown 8 % of patients having fatal anaphylactic
reactions after receiving a bolus injection [2]. The current
work explores possibility of delivering IONPs across the
intestinal barrier to circulating blood to be targeted to a distant
diseased tissue especially hepatic lesion. Tackling the intesti-
nal mucosal barrier for effective delivery to systemic circula-
tion is the challenge, as the carrier of IONPs should clearly
adhere onto the intestinal epithelium to follow an uptake
pathway. A submicron (200 nm or less) size and cationic to
near neutral particle surface charge are important criteria for
increased residence time, as glycocalyx making the mucosa is
negatively charged. We are reporting a Folate-chitosan coated
IONP-PLGA nanoparticles having a core-shell nanostructure,
where shell protects the core containing IONPs from degra-
dation, stable at varying GI pH and enhances GI uptake of the
particles. The material has been characterized for Size
(< 200 nm), Charge (positive to near neutral), IONP encapsu-
lation efficiency (60%), folate chitosan coating efficiency (via
Nitrogen-Carbon ratio) and IONP relaxivity after loading/
coating (60 mM-1s-1). The material was subjected to phantom
MR imaging of HepG2 hepatocellular carcinoma cells, which
showed enhanced contrast due to their cationic nature. As
these particles were found to enhance MR contrast of oral
cancer cells, KB, via folate receptor targeting, future
biodistribution studies may pour insights if folic acid can
facilitate targeting these structures to any non-hepatic tissues,
after GI absorption.
077. NANOBIOSENSINGDEVICES FORDETECTION
OF MESOTHELIN IN CANCER CELL LINES
Singh KP1, Puri A2, Ahlawat S1, Prusty AK1. 1Bio-Nanotech-
nology Research Laboratory, Biophysics Unit, G.B. Pant
University of Agriculture and Technology, India, 2Basic
Research Lab, Center for Cancer Research, National
Cancer Institute, Frederick, MD 21702-1201.
Metallic, polymeric and carbon-based materials and recently
graphene-based materials are considered viable choices for
signal amplification of biosensors. We have proposed a flow
injection assay of the mesothelin using quartz crystal microbal-
ance (QCM) biosensor. Gold-coated quartz crystal functional-
ized with 16-mercaptohexadecanoic acid (MHDA) self assem-
bled monolayer was used to fabricate a sensitive
immunobiosensor for mesothelin detection and compared with
gold nanoparticles (AuNPs) and graphene oxide (GONPs)
nanoparticles. Mesothelin specific polyclonal antibody was
covalently immobilized on MHDA modified gold surface of
quartz crystal using N-ethyl-N′-(3-dimethylaminopropyl)
carbodiimide and N-hydroxysuccinimide (EDC/NHS) chemis-
try. Ethanolamine was used as a blocker to prevent nonspecific
adsorption. A homemade siphon flow system was designed
using a clamp stand, Stanford Research System-flow cell, pre-
cision silicon tubing, stopper, 6-port valve and syringe. Phos-
phate buffer saline solution of pH 7.4 was used as the carrier
buffer@ rate 40μ liters per minute for the experiment to get the
stable base line of the resonance frequency of the crystal.
Different concentrations of pure mesothelin, AuNP-
mesothelin and GONP-mesothelin were allowed to flow for
binding with the antibody immobilized on the surface modified
crystals. The resonance frequency variation of the crystal was
observed by a quartz crystal microbalance until a stable re-
sponse is obtained for various concentrations of mesothelin.
The frequency changes revealed a close correlation with
Mesothelin concentrations in the measurement range of
100 pg.mL-1 to 100 ng.mL-1. The GO-coated sensing units
provide improved sensitivity of mesothelin detection.
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Supported by: This project is part of the joint venture support-
ed by Intramural to India (I-to-I) funding for treatment and
prevention of sexually transmitted diseases awarded to Dr.
Anu Puri (NCI) and Dr. K.P. Singh (Pantnagar University).
078. STUDIES ON ENCAPSULATION OF PHOTO-
DYNAMIC ANTICANCER AGENTS, CHLORIN E6
AND HPPH IN PHOTOACTIVABLE “POCKET”
LIPOSOMES CONTAINING DC8,9PC
Thayer D, Sine J, Blumenthal R, Puri A. Basic Research Lab,
Center for Cancer Research, National Cancer Institute-
Frederick, Frederick, MD, 21702.
We recently reported the release of a water soluble dye, calcein
(Ex/Em 490/517 nm), from liposomes containing dipalmitoyl
phosphatidylcholine (DPPC) andDC8,9PC upon laser treatment.
DC8,9PC has the hypothesized effect of forming pockets in the
liposome membrane allowing for photo-activated compounds to
more easily permeate the liposomal membrane. To develop these
formulations for dual drug delivery and in vivo applications, we
have utilized two near-infrared Photodynamic Therapy (PDT)
drugs, Chlorin e6 (ex/em 400/660 nm) and 2-(1-Hexyloxyethyl)-
2-devinyl pyropheophorbide-a (HPPH) (ex/em 410/670 nm).
Liposomes loaded with calcein and with or without either of
the PDT drugs underwent 660 nm laser-triggered release of
calcein and were analyzed for fluorescence. Our data shows that
inclusion of HPPH in the formulations enhanced calcein entrap-
ment. In contrast, Chlorin e6 had significant reduction in the
entrapment of calcein under identical conditions. Control sam-
ples (loaded only with calcein) did not promote calcein release
upon 660 nm laser exposure. Based on our observations, we
have reason to believe that the two PDT drugs partition into the
lipid membrane through different mechanisms. These differing
mechanisms affect how calcein is encapsulated into the aqueous
core of the liposome. Therefore, we propose that HPPH is
preferential to Chlorin e6 in our phototriggerable drug delivery
platforms, while the specific dynamics of membrane partitioning
still remain unknown. Going forward, the efforts of this research
will be to determine the specific partitioning mechanism of
HPPH as well as conclude the optimum procedure for dual-
drug delivery through our liposome formulations.
079. ADVANCED EFFICIENCYAND SPECIFICITY OF
ANTI-HIVDRUGSCONJUGATEDWITHNANOGELS
Warren G1, Lu Y1, Makarov E2, Senanayake T1, Gorantla S2,
Poluektova LY2, Vinogradov SV1. 1Department of Pharma-
ceutical Sciences and 2Department of Pharmacology and
Experimental Neuroscience, University of Nebraska
Medical Center, Omaha, NE 68198.
The effectiveness of anti-HIV drugs is limited to their ability to
accumulate in infected immune cells. Here we introduce novel
targeted nanogel conjugates with nucleoside reverse transcriptase
inhibitors (NRTIs) with enhanced antiviral activity, which are
able to efficiently accumulate in macrophages. In the first type of
conjugates, NRTIs are connected to nanogels via biodegradable
succinate linker, while in the second type NRTIs are attached via
an oligophosphate linker. Nanogel design was based on non-
toxic biodegradable biopolymers (e-polylysine and dextrin)
modified by cholesterol moieties and formed compact particles
with hydrophobic core after sonication in aqueous media. High
drug loading (up to 40 % by weight) could be obtained in these
nanogel-NRTIs. Nanogel-linked Zidovudine, Lamivudine or
Abacavir, components of therapeutic Combivir and Trizivir
cocktails, have been evaluated in HIV-infected human
monocyte-derived macrophage (MDM). Ten-fold inhibition of
HIV-1 activity in the infected MDMs was achieved at concen-
tration two to nine times lower compared to conventional drugs.
Dual- and triple-drug nanogel-NRTI cocktails, similar to thera-
peutic NRTI cocktails, also showed significantly higher antiviral
activity in the infected MDMs compared to nanogel-NRTIs.
Novel nanodrugs allowed an extended, up to 10 days, drug
release kinetics, and exhibited preferential uptake in macro-
phages. Efficacy of nanogel-NRTI uptake was enhanced three-
fold by the covalent modification with glutathione moieties. In
addition, these antivirals demonstrated much lower toxicity in
variety of cells (e.g., macrophages, brain capillary endothelial
cells, astrocytes, microglia, etc.) than NRTIs. Additional modifi-
cation with brain-specific peptides was successfully applied to
the CNS delivery of nanogel-NRTIs. Current work will be
extended for evaluation of antiviral efficacy using an in vivo
humanized HIV mouse model in order to assess therapeutic
advantages of new nanodrugs.
080 . NOVEL SELF-ASSEMBLY AND PH-
SENSITIVE ANTICANCER DRUG CARRIERS
(POLY(AMIDO AMINE)-ANILINE PENTAMER)-
MOD I F I ED POLYETHYLENE GLYCOL
LOADINGWITH DOXORUBIC
Yeh J-M, Chang, K-C, Wu P-S. Chung Yuan Christian
University Taiwan 32023, R.O.C.
A novel system that self-assembly and pH-sensitive drug
release is based on aniline pentamer (AP) as a shell conjugated
to polyethylene glycol (PEG)-modified dendrimers
(PAMAM) with doxorubicin (DOX) (DOX-PEG-PAMAM-
AP) has been constructed and characterized. Firstly, the higher
generations (G=5) are demonstrated to self-assemble into
bilayer vesicles owing to the strong tendency of the AP to
form PAMAM-AP G5. Subsequently, PAMAM-AP G5 mod-
ified hydrophilic and biocompatibility segment PEG synthesis
of PEG-PAMAM-AP G5. Then, load with the anticancer drug
(DOX) to synthesis DOX-PEG-PAMAM-AP G5. The use of
amphiphilic characteristics form these aggregations as new
drug carrier to explore the ability to cytotoxicity of human
breast cancer cells (MCF-7), and compare the drug release
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efficiency. The results show that the novel anticancer drug
carriers (DOX-PEG-PAMAM-AP G5) could effectively en-
hance the DLE and drug cumulative release at pH=4.0 com-
pared with DOX-PEG-PAMAM G5. The cytotoxicity of
MCF-7 of DOX-PEG-PAMAM-AP G5 is similar to DOX.
081. OPTICALLY-ENHANCED DELIVERY AND
TRACKING OF THERANOSTIC NANOPARTICLES IN
GLIOBLASTOMA IN ANIMALMODEL
Yuan H. Duke University, Durham, NC 27708.
Cancer nanotheranostics provide tremendous biomedical op-
portunities for cancer diagnosis, imaging, and therapy. Such a
“theranostics” strategy could potentiate translational research
and improves precision medicine. Brain malignancy, due to
the presence of blood-brain barrier (BBB) that hinders
paracellular flux of drug molecules into brain parenchyma,
remains one of the most challenging tumor types. Great diffi-
culty existed in designing a theranostic agent with enhanced
property to enter brain tumor parenchyma. In this article, we
present a theranostic nanoplatform that acts as contrast agent,
photothermal therapeutic agent, and blood-brain tumor barrier
(BBTB) permeabilization agent. We first demonstrate a supe-
rior optical property of our nanoplatform as contrast agent
under high-resolution depth-resolved multiphoton microsco-
py. We then examine the microscopic distribution of
PEGylated nanoparticles in tumor brain animal models.
Nanoparticles were found in both endothelial cells and inter-
stitial matrices. We also examine the effect of different
diameters and two potential BBTB penetrating surface
functionalizations (e.g., TAT peptide, angiopep2 peptides).
Furthermore, since current BBB disrupting agents (e.g., man-
nitol, focused ultrasound) typically suffer from poor spatial
control, we demonstrated a novel photothermal-induced
BBTB permeabilization with highly selective spatial delivery.
Fine-tuning the irradiating energy induced gentle disrup-
tion of the vascular integrity and secondary inflammatory
reaction, causing short-term extravasation of nanoparticles
into tumor parenchyma only at the irradiated site. Based
on these findings, we conclude that our theranostic
nanoplatform is both a strong biocompatible contrast agent
and a powerful BBTB permeabilizing agent. With more
optimization, we envision a strong potential in future brain
tumor imaging and therapy.
082. A MIXED-LINEAGE KINASE 3 INHIBITOR
FACILITATES NANOFORMULATED ANTIRETRO-
VIRALTHERAPY CLEARANCE OF HIV-1 ASSEMBLY
Zhang G1, Dash PK1, Guo D1, Wiederin JL1, Ciborowski P1,
Goodfellow VS2, McMillan J1, Gorantla S1, Gelbard HA3,
GendelmanHE1. 1University of NebraskaMedical Center, Oma-
ha, NE, 68198; 2Califia Bio, Inc., San Diego, CA, 92121;
3University of Rochester Medical Center, Rochester, NY, 14642.
Antiretroviral therapy (ART) has improved the quality of life
for infected people. However, despite ART viral replication
continues, albeit at low levels in reservoirs of persistent infec-
tion. Eradication of infection remains the major goal of HIV
researchers. Recently, a novel mixed-lineage kinase-3
(MLK3) inhibitor (URMC-099) with promising immune and
neural modulatory activities was discovered. Surprisingly, the
drug potentiated antiretroviral activities of nanoformulated
long-acting ART. Isobaric tag for relative and absolute quan-
titation (iTRAQ) performed using the mixed-lineage kinase
URMC-099-treated macrophages potentiated antiretroviral
actions. Nanoformulated atazanavir (nanoATV) with dose
escalated URMC-099 was tested for antiretroviral activities
in HIV-1ADA infected MDM. Viral DNA and RNA, Gag
proteins and reverse transcriptase activities were assessed.
Subcellular endosomal trafficking (Rab 5, 7, 8 and 14) of
ART nanoparticles were investigated by Western blot, confo-
cal microscopy and HPLC. Humanized NOD/scid-IL-
2Rgcnull mice were infected with HIV-1ADA then URMC-
099 and nanoATV/r. Peripheral viral load (VL), humanCD4+ T
cells, and lymphoid and brain tissues were studied. URMC-099
increased expression of the RAS-related GTP-binding proteins
Rab 7, 8 and 14 in HIV-1 infected MDM. NanoATVantiretro-
viral activities were potentiated by URMC-099 with reductions
in viral gene products. URMC-099 increased ATV concentra-
tions in Rab7 endosomes. Highest CD4+ T cell numbers and
lowest VL were in infected humanized mice treated with
URMC-099 and nanoATV. Histopathological tests showed de-
creased numbers of HIV-1p24 cells with both drugs compared
to nanoATV alone in lymphoid tissues. iTRAQ showed Rab7
changes specifically in infected MDM. URMC-099 potentiates
nanoATV responses to restrict HIV-1 and protect CD4+ T
lymphocytes. This occurs, in part, by sustaining ART levels.
These effects may represent a novel means for viral clearance.
Supported by: NIH P01DA028555 and R01 A1097550
(HEG); P01MH064570 (HAG)
083. TARGETED (-)-EPIGALLOCATECHIN GAL-
LATE LOADED LIPID NANOPARTICLES INHIBIT
FOAM CELL FORMATION
Zhang J, Nie S, Wang S. Nutritional Sciences Program, Texas
Tech University, Lubbock, TX 79409.
Macrophages play an important role in atherosclerotic lesion
progression by facilitating cholesterol accumulation and in-
creasing inflammatory responses in aortic walls. After accu-
mulating cholesterol, macrophages can be transformed into
foam cells, which characterize the atherosclerotic lesion. (-)-
Epigallocatechin gallate (EGCG), a natural compound found
in green tea, has a potential to inhibit foam cells formation
through decreasing macrophages cholesterol accumulation
and inflammatory response.We have successfully synthesized
targeted EGCG loaded lipid nanoparticles (T-nanoE). The
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EGCG stability was significantly increased by the nanoparti-
cles. T-nanoE had higher binding affinity to macrophages than
non-targeted EGCG loaded lipid nanoparticles (nanoE). After
knocking down a scavenger receptor, T-nanoE had a low
binding affinity to macrophages. As compared to native
EGCG, EGCG nanoparticles significantly decreased macro-
phage cholesteryl ester content measured using a high perfor-
mance liquid chromatography (HPLC) system. EGCG nano-
particles also decreased the expression of monocyte
chemoattractant protein 1 (MCP-1) in macrophages. In con-
clusion, lipid nanoparticles increase EGCG stability. T-nanoE
can target to macrophages. Both T-nanoE and nanoE inhibit
foam cell formation. T-nanoE might be better than nanoE.
Supported by: NIH NCCAM Grant Number R15AT007013
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